alanine has been researched along with gs-7340 in 362 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (1.10) | 29.6817 |
| 2010's | 154 (42.54) | 24.3611 |
| 2020's | 204 (56.35) | 2.80 |
| Authors | Studies |
|---|---|
| Cihlar, T; Cundy, KC; Eisenberg, E; He, GX; Lee, WA; Mulato, A; Swaminathan, S | 1 |
| Bischofberger, N; Blackwood, EJ; Colón, R; Kearney, BP; Lawson, JR; Lee, WA; Marthas, ML; Sexton, JJ; Van Rompay, KK | 1 |
| Birkus, G; Cihlar, T; Gibbs, C; Kutty, N; Lee, W; Liu, X; MacArthur, H; McDermott, M; Swaminathan, S; Wang, R | 1 |
| Birkus, G; Cihlar, T; He, GX; Kutty, N; Lee, W; McDermott, M; Mulato, A | 1 |
| Babusis, D; Lee, WA; Phan, TK; Ray, AS; Watkins, WJ | 1 |
| Adams, DR; Butler, K; Cong, ME; Garcia-Lerma, JG; Hanson, D; Hendry, RM; Heneine, W; Kersh, EN; Luo, W; McNicholl, JM; Youngpairoj, AS; Zheng, Q | 1 |
| Lepist, EI; Maclennan, K; Murray, B; Phan, TK; Ray, AS; Roy, A; Tong, L | 1 |
| Berger, D; Bredeek, UF; Callebaut, C; DeJesus, E; Fordyce, MW; Markowitz, M; Ramanathan, S; Rhee, MS; Ruane, PJ; Yale, K; Zhong, L | 1 |
| Coakley, D; Kearney, B; Lee, WA; Markowitz, M; Miller, MD; Ruane, P; Squires, K; Wulfsohn, M; Zhong, L; Zolopa, A | 1 |
| Babusis, D; Bam, RA; Birkus, G; Cihlar, T; Yant, SR | 1 |
| Bam, RA; Cihlar, T; Yant, SR | 1 |
| Brar, I; Callebaut, C; Elion, R; Fordyce, MW; Martin, H; McCallister, S; Ortiz, R; Post, F; Sax, PE; Wang, H; Zolopa, A | 1 |
| Agarwal, K; Cheng, W; Flaherty, JF; Foster, GR; Fung, SK; Gane, EJ; Lawson, E; McHutchison, JG; Nguyen, TT; Ryder, SD; Sicard, E; Subramanian, GM; Zhao, S | 1 |
| Callebaut, C; Cao, H; Cheng, A; Crofoot, G; Custodio, J; Das, M; Flamm, JA; Gathe, J; Liu, HC; Martin, H; McCallister, S; McDonald, C; Mills, A; Saag, M; Scribner, A; Shalit, P; Shamblaw, D; Thomas, A; Yan, M | 1 |
| Babusis, D; Hao, J; Lepist, EI; Murakami, E; Park, Y; Ray, AS; Wang, T | 1 |
| Baeten, JM; Wyatt, C | 1 |
| Andrade-Villanueva, J; Callebaut, C; Cao, H; Cheng, AK; Crofoot, G; Custodio, JM; DeJesus, E; Fordyce, MW; Koenig, E; Martin, H; McCallister, S; Molina, JM; Oka, S; Plummer, A; Podzamczer, D; Post, F; Pozniak, A; Saag, M; Sax, PE; Thompson, M; Trottier, B; Wohl, D; Yin, MT; Zhong, L | 1 |
| Baum, MM; Beliveau, M; Fanter, R; Gunawardana, M; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Remedios-Chan, M; Smith, TJ; Yang, F | 1 |
| Callebaut, C; Johnson, A; Margot, NA; Miller, MD | 1 |
| Callebaut, C; Miller, MD; Stepan, G; Tian, Y | 1 |
| Bam, RA; Birkus, G; Cihlar, T; Frey, CR; Stray, KM; Tsai, L; Willkom, M; Yant, SR | 1 |
| Andrade-Villanueva, J; Arribas, JR; Brar, I; Brunetta, J; Cavassini, M; Cheng, AK; DeJesus, E; DiPerri, G; Elion, R; Girard, PM; Huhn, G; Koenig, E; Liu, YP; Madruga, JV; McCallister, S; Mills, A; Orkin, C; Plummer, A; Shamblaw, D; Stephens, JL; Van Lunzen, J; Wohl, DA | 1 |
| Fordyce, MW; Hitchcock, MJ; Ray, AS | 1 |
| Wyatt, CM | 1 |
| Arribas, JR; Brinson, C; Brunetta, J; Callebaut, C; Cheng, A; Cheret, A; Clarke, A; Clumeck, N; Das, M; Fordyce, M; Mussini, C; Oka, S; Rashbaum, B; Sax, PE; Stephens, J; Tashima, K; Tebas, P; Wohl, D; Zhong, L | 1 |
| Callebaut, C; Fordyce, M; Kitrinos, KM; Margot, NA; McCallister, S; Miller, MD | 1 |
| Aguiar, C; Antela, A; Boffito, M; Compston, J; Di Perri, G; Hendry, BM; Mallon, P; Pourcher-Martinez, V | 1 |
| Dewar, RL; Kopp, JB; Lane, HC; Maldarelli, F; Manion, MM; Mikula, JM; Norman-Wheeler, JF; Ober, AG; Pau, AK; Suarez, LM | 1 |
| Warpakowski, A | 1 |
| Desai, T; Johengen, D; Luecke, E; McGowan, I; Rothrock, G; Schlesinger, E; van der Straten, A | 1 |
| Abram, ME; Brinson, C; Cheng, AK; Clumeck, N; Daar, ES; DeJesus, E; Gallant, JE; Johnson, M; Morales-Ramirez, J; Osiyemi, O; Plummer, A; Raffi, F; Rhee, MS; Ruane, P; Ward, D; Yan, M | 1 |
| Gazzard, B | 1 |
| De Clercq, E | 3 |
| Beraud, G; Chagneau-Derrode, C; Garcia, M; Godet, C; Le Moal, G; Roblot, F | 1 |
| Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S | 1 |
| Deeks, ED; Greig, SL | 1 |
| Jones, R; Levy, JB; Milburn, J | 1 |
| Custodio, JM; Fordyce, M; Garner, W; Kearney, BP; Ling, KH; Ramanathan, S; Vimal, M | 1 |
| Bischoff, M | 1 |
| Babusis, D; Deyounks, F; García-Lerma, JG; Heneine, W; Massud, I; Miller, MD; Mitchell, J; Ray, AS; Rooney, JF | 1 |
| Gibson, AK; Nambiar, PH; Schafer, JJ; Shah, BM | 1 |
| Lu, X; Wang, H; Xu, N; Yang, X | 1 |
| Bannerman, T; Cheng, A; Das, M; Dinoso, J; Fang, L; Fordyce, MW; Funderburg, NT; Kulkarni, M; Liu, HC; Mantini, J; McCallister, S; McComsey, GA; Song, Q; Thornton, B; Zhang, Y | 1 |
| Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L | 1 |
| Albert, J; Blaxhult, A; Carlander, C; Eriksen, J; Flamholc, L; Gisslén, M; Josephson, F; Karlström, O; Navér, L; Sönnerborg, A; Svedhem, V; Yilmaz, A | 1 |
| Havlíčková, K; Husa, P; Snopková, S | 1 |
| Kitrinos, KM; Liu, Y; Miller, MD | 1 |
| Rizza, S; Sampath, R; Temesgen, Z; Zeuli, J | 1 |
| Destache, CJ; Fan, W; Kang, G; Li, Q; Mandal, S; Prathipati, PK; Yuan, Z; Zhou, Y | 1 |
| Babusis, D; Callebaut, C; Kitrinos, K; Liu, Y; Miller, M; Ray, A | 1 |
| Benson, P; Brinson, C; Cheng, A; Crofoot, G; DeJesus, E; Dretler, R; Martin, H; Mills, A; Peloquin, J; Quirk, E; Sax, PE; Ward, D; Wei, X; White, K | 1 |
| Cao, H; Cheng, A; Crofoot, G; de Wet, J; DeJesus, E; LaMarca, A; Liu, Y; Martorell, CT; Mills, A; Molina, JM; Porter, D; Post, FA; Quirk, E; Ramgopal, M; Ruane, P; SenGupta, D; Stellbrink, HJ; Valero, IP | 1 |
| Cao, H; Cheng, A; Crofoot, G; de Wet, J; DeJesus, E; LaMarca, A; Lazzarin, A; Liu, HC; Mills, A; Orkin, C; Podzamczer, D; Porter, D; Quirk, E; Ramgopal, M; Rijnders, B; Rockstroh, J; Ruane, P; SenGupta, D; Stoeckle, M; Thalme, A; Vandercam, B | 1 |
| Abram, ME; Bellos, N; Cheng, A; Clarke, A; Daar, E; Gallant, J; Henry, K; Orkin, C; Raffi, F; Rhee, MS; Santana-Bagur, J; Scarsella, A; Slama, L; Stein, DK; Yan, M | 1 |
| Arribas, JR; Callebaut, C; Cheng, A; Clarke, AE; Das, M; DeJesus, E; Guo, S; Haas, B; McCallister, S; McDonald, C; Plummer, A; Sax, PE; Thompson, M; Wang, H; Wohl, DA | 1 |
| Callebaut, C; Cox, S; Johnson, A; Margot, N; Miller, M; Ram, R | 1 |
| Cottrell, ML; Emerson, CW; Garrett, KL; Gay, C; Kashuba, ADM; McCallister, S; Peery, A; Prince, HMA; Rooney, JF; Schauer, A; Sykes, C | 1 |
| Gotham, D; Hill, A; Pozniak, AL | 1 |
| Boffito, M; Flexner, CW; Maartens, G | 1 |
| Karris, MY | 1 |
| Acharya, SK; Agarwal, K; Chan, HL; Chen, CY; Chowdhury, A; Chuang, WL; Flaherty, JF; Fung, S; Gaggar, A; Gane, E; Hui, AJ; Janssen, HL; Kim, HJ; Kitrinos, KM; Lim, YS; Lin, L; Massetto, B; McHutchison, JG; Mehta, R; Seto, WK; Subramanian, GM; Tsang, TY | 1 |
| Acharya, SK; Brunetto, M; Buti, M; Cathcart, AL; Chan, HL; Chuang, WL; Flaherty, JF; Gaggar, A; Gane, E; Hui, AJ; Izumi, N; Janssen, HL; Kim, K; Lim, YS; Marcellin, P; Massetto, B; McHutchison, JG; Mehta, R; Pan, CQ; Seto, WK; Stepanova, T; Subramanian, GM | 1 |
| Abram, ME; Callebaut, C; Kulkarni, R; Margot, NA; Miller, MD; Porter, D; White, K; Wong, P | 1 |
| Abdul Basit, S; Dawood, A; Gish, R; Ryan, J | 1 |
| Chan, HLY; Scott, LJ | 1 |
| Ikushima, I; Irie, S; Ishikawa, T; Nemoto, T; Ninomiya, N; Yamada, H | 1 |
| Darcis, G; Moutschen, M; Sauvage, AS | 1 |
| Gallagher, A; Gracey, DM; Quan, D | 1 |
| Brar, I; Cheng, A; Custodio, J; Daar, ES; Gallant, J; Girard, PM; Lazzarin, A; Martin, H; Mills, A; Orkin, C; Podzamczer, D; Quirk, E; Rockstroh, J; Tebas, P; Wei, X; White, K; Wohl, D | 1 |
| Antinori, A; Cheng, A; Custodio, J; DeJesus, E; Garner, W; Koenig, E; Montes, ML; Pozniak, A; Quirk, E; Reynes, J; Sax, PE; SenGupta, D; Slim, J; Stellbrink, HJ; White, K; Workowski, K | 1 |
| Chen, Q; Jin, X; Ouyang, B; Peng, Y; Sun, J; Wang, G; Zhang, J; Zhen, L; Zhou, F | 1 |
| Atta, MG; Choi, MJ; Fine, D; McMahon, BA; Novick, TK; Rosenberg, AZ | 1 |
| Baldelli, S; Cattaneo, D; Clementi, E; Galli, M; Gervasoni, C; Giacomelli, A; Mazzali, C; Meraviglia, P; Milazzo, L; Minisci, D; Resnati, C; Rizzardini, G | 1 |
| Hsu, YC; Nguyen, MH; Wei, MT | 1 |
| Ferrara, SM; Santantonio, T; Sica, S; Tartaglia, A | 1 |
| Guaraldi, G | 1 |
| Reinke, T | 1 |
| Furusyo, N; Nguyen, MH; Ogawa, E | 1 |
| Bodwell, J; Kashuba, ADM; Patel, MV; Rodriguez-Garcia, M; Shen, Z; Wira, CR | 1 |
| Asriel, B; Chan, L; Eaton, EF; Wyatt, CM | 1 |
| Bares, SH; Dyavar, SR; Fletcher, CV; Havens, J; Lee, S; O'Neill, J; Podany, AT; Scarsi, KK; Swindells, S | 1 |
| Barth, A; Lai, MT; Ma, B; McHale, CM | 1 |
| Grossi, G; Lampertico, P; Loglio, A; Viganò, M | 1 |
| DeJesus, E; Haas, B; Liu, YP; Makadzange, T; Margot, N; McCallister, S; Mills, A; Ramgopal, MN; Segal-Maurer, S | 1 |
| Buti, M; Esteban, R; Riveiro-Barciela, M | 1 |
| Ensign, LM; Hoang, T; Hummert, P; Marzinke, MA; Parsons, TL | 1 |
| Avihingsanon, A; Cao, H; Cheng, A; Hagins, D; Hodder, S; Jiang, S; Kido, A; Kityo, C; Kulkarni, R; Squires, K | 1 |
| Callebaut, C; Cox, S; Margot, N; Miller, M | 1 |
| Bowden, BH; Smith, DE; Tom, M | 1 |
| Begley, R; Custodio, JM; Das, M; Kearney, BP; Ling, J; Zhong, L | 1 |
| Satsangi, S | 1 |
| Agarwal, K; Ahn, SH; Bae, H; Bhardwaj, N; Brunetto, M; Buti, M; Cathcart, AL; Çelen, MK; Chan, HLY; Chuang, WL; Flaherty, JF; Fung, S; Furusyo, N; Gaggar, A; Gane, EJ; Izumi, N; Janssen, HLA; Lau, AH; Lim, YS; Lin, L; Mani Subramanian, G; Marcellin, P; Pan, CQ; Seto, WK; Shalimar, D; Sharma, M; Suri, V; Trinh, H; Yoon, KT | 1 |
| Clotet, B; Negredo, E | 1 |
| Bensouda, S; Cone, RA; Date, AA; Ensign, LM; Fuchs, EJ; Gumber, S; Hanes, J; Hendrix, C; Hoang, T; Marzinke, M; Ortiz, JO; Rohan, L; Villinger, F; Xiao, P; Young, TW | 1 |
| Deeks, ED | 1 |
| Harris, M | 1 |
| Andreatta, K; Cheng, A; Creticos, C; Crofoot, G; Custodio, J; Daar, ES; DeJesus, E; Graham, H; Koenig, E; Liu, YP; Martin, H; Molina, JM; Oguchi, G; Quirk, E; Rockstroh, JK; Ruane, P | 1 |
| Clarke, A; Garner, W; Laouri, M; Maggiolo, F; Martin, H; Quirk, E; Wohl, D | 1 |
| Alsunaid, SR; Ashraf, H; Soubani, AO | 1 |
| Bares, SH; Havens, JP; Lee, SS; O'Neill, JL; Podany, AT; Sayles, HR; Scarsi, KK; Swindells, S | 1 |
| Cameron, SA; Cheshenko, N; Frank, B; Fredricks, D; Herold, BC; Keller, MJ; Mesquita, PM; Reagle, K; Sinclair, S; Srinivasan, S; Taneva, E; Weinrick, B | 1 |
| Aralaguppe, SG; Neogi, U; Njenda, DT; Rao, R; Sarafianos, SG; Singh, K; Sönnerborg, A | 1 |
| Álvarez, H; Díaz-Cambre, H; García-González, J; Llibre, JM; Mariño, A; Valcarce, N | 1 |
| Chen, J; Cottrell, ML; Dumond, JB; Garrett, KL; Maas, BM; Prince, HA; Schauer, AP; Sykes, C; White, N | 1 |
| Domingo, P; Gutierrez, MDM; Mateo, MG; Vidal, F | 1 |
| Bogner, JR; Gomez, M; Härter, G; Roider, J; Seybold, U | 1 |
| Byland, E; Canupp, K; Dunlap, J; Mospan, C; Mospan, G; Whitaker, WB; Xiong, L | 1 |
| Balboa-Barreiro, V; Castro-Iglesias, Á; Cid-Silva, P; Fernández-Bargiela, N; López-Calvo, S; Margusino-Framiñán, L; Martín-Herranz, I; Mena-De-Cea, Á; Míguez-Rey, E; Poveda, E; Vázquez-Rodríguez, P | 1 |
| Bártolo, I; Borrego, P; Caixas, U; Gomes, P; Gonçalves, F; Pinto, IV; Taveira, N | 1 |
| Baugh, B; Crauwels, HM; Hijzen, A; Opsomer, M; Van Landuyt, E; Vanveggel, S | 1 |
| Bandera, A; Bozzi, G; Colella, E; Gori, A; Squillace, N | 1 |
| Andreoni, M; Cerva, C; Maffongelli, G; Malagnino, V; Sarmati, L; Teti, E | 1 |
| Cottrell, ML; Garcia, B; Imaz, A; Kashuba, ADM; Morenilla, S; Niubó, J; Perez, E; Podzamczer, D; Tiraboschi, JM | 1 |
| Ahn, A; Bae, HS; Chang, M; Fong, TL; Lee, BT; Lim, C; Tien, A | 1 |
| Capetti, AF; Cossu, MV; Giacomet, V; Rizzardini, G; Zuccotti, G | 1 |
| Bahr, NC; Yarlagadda, SG | 2 |
| Mesplède, T; Pham, HT | 1 |
| Bodwell, J; Patel, MV; Rodriguez-Garcia, M; Shen, Z; Wira, CR | 1 |
| Acosta, RK; Chang, S; Garner, W; Lutz, J; Majeed, S; Martin, H; Martin, R; Quirk, E; SenGupta, D; Wei, X; White, KL; Willkom, M | 1 |
| Arabzadeh, V; Davallo, M; Goudarzi, N; Sohrabi, MR | 1 |
| Bonora, S; Calcagno, A; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Mogyorosi, K | 1 |
| Arribas, JR; Brainard, D; Carter, C; Clarke, AE; Das, M; Elion, RA; Eron, JJ; Esser, S; Guo, S; Gupta, SK; Martin, H; Mudrikova, T; Negredo, E; Orkin, C; Podzamczer, D; Post, FA; Pozniak, AL; Rockstroh, JK; Sax, PE; SenGupta, D; Stellbrink, HJ; Waters, L; Wohl, DA; Zhong, L | 1 |
| Hiraoka, A; Izumoto, H; Kitahata, S; Kondoh, K; Michitaka, K; Ninomiya, T; Tsubouchi, E; Ueki, H; Yamago, H | 1 |
| Blake, K; Chen, J; Cohen, MS; Dumond, JB; Gay, CL; Greene, SA; Nelson, JAE; Prince, HMA; Schauer, AP; Sykes, C | 1 |
| Arends, JE; Hoepelman, AIM; Mudrikova, T; Thielen, MAJ; Van Welzen, BJ | 1 |
| Fang, B; Ge, Q; Kang, X; Li, Z; Ma, H; Zhao, L; Zhou, Z | 1 |
| Acosta, R; Antinori, A; Baumgarten, A; Brainard, D; Brinson, C; Clarke, A; Collins, SE; Hagins, D; Martin, H; Ramgopal, MN; Thompson, MA; Wei, X; Wohl, DA; Yazdanpanah, Y | 1 |
| Barber, TJ | 1 |
| Acosta, R; Albrecht, H; Arribas, JR; Brainard, D; Collins, SE; Creticos, C; Maggiolo, F; Martin, H; Martorell, CT; Sax, PE; Stellbrink, HJ; Stephens, JL; Wei, X | 1 |
| Di Perri, G; Esser, S; Lelièvre, JD; Parczewski, M; Shafran, SD | 1 |
| Fujii, T; Kawasoe, K; Nitta, K; Ohta, A | 1 |
| Hagiwara, S; Ida, H; Komeda, Y; Kudo, M; Minami, Y; Nishida, N; Takita, M; Ueshima, K | 1 |
| Kim, WR; Kwo, PY; Mannalithara, A; Sripongpun, P | 1 |
| Brown, K; Cunningham, D; De Wit, S; Eron, JJ; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Petrovic, R; Post, FA; Pulido, F; Van Landuyt, E | 1 |
| Kaplun, O; Psevdos, G | 1 |
| Chen, J; Cheng, J; Li, L; Ma, Y; Yu, Y; Zhao, J; Zhou, L | 1 |
| Conway-Washington, C; Dinh, C; Fountain, J; Haaland, RE; Hall, L; Holder, A; Kelley, CF; Livermont, T; Lupo, LD; Martin, A | 1 |
| Babusis, D; Callebaut, C; Cong, ME; Deyounks, F; Dinh, C; García-Lerma, JG; Heneine, W; Holder, A; Johnson, R; Khalil, G; Lipscomb, J; Massud, I; McCallister, S; Nishiura, K; Pan, Y; Park, Y; Rooney, JF; Ruone, S | 1 |
| Andreatta, K; Chang, S; Graham, H; Liu, H; Liu, YP; Martin, H; Martin, R; Quirk, E; Wei, L; White, KL; Willkom, M | 1 |
| Kearney, B; Kolaris, C; Ling, KHJ; Majeed, SR; Tarnowski, T; Xiao, D; Zondlo, S | 1 |
| Brown, K; DeJesus, E; Eron, JJ; Girard, PM; Huhn, GD; Lathouwers, E; Luo, D; Molina, JM; Nettles, RE; Orkin, C; Petrovic, R; Van Landuyt, E; Wong, EY | 1 |
| Coelho, LE; Grinsztejn, B; Landovitz, RJ; Torres, TS; Veloso, VG | 1 |
| Burgi, A; Letendre, SL; Little, SJ; Ma, Q; Morse, GD; Ocque, AJ; Sanders, C | 1 |
| Castagna, A; Gianotti, N | 1 |
| Das, M; Haubrich, R; Maggiolo, F; Mateo-Garcia, MG; McNicholl, I; Molina, JM; Ong, E; Piontkowsky, D; Pulido, F; Raffi, F; Rizzardini, G; Shao, Y | 1 |
| Bernasconi, E; Calmy, A; Cavassini, M; Fehr, J; Furrer, H; Fux, CA; Kovari, H; Rauch, A; Roth, B; Stöckle, M; Surial, B; Wandeler, G | 1 |
| Acosta, RK; Avihingsanon, A; Cao, H; Chetchotisakd, P; DeJesus, E; Gankina, N; Hagins, D; Kityo, C; Koenig, E; Makadzange, T; Martin, H; Pokrovsky, V; Quirk, E; Stephens, JL; Supparatpinyo, K; Voronin, E; Wang, H | 1 |
| Álvarez, H; Llibre, JM | 1 |
| Hollenbeck, BL; Kishore, S; Lee, MSL; Padival, S | 1 |
| Saag, MS | 1 |
| Goldstein, RH; Walensky, RP | 1 |
| Bailey, AC; Barbini, B; Burling, K; Campbell, L; Hamzah, L; Ibrahim, F; Jones, R; Musso, CG; Post, FA; Williams, D | 1 |
| Koenig, HC; Lalley-Chareczko, L; Moorthy, GS; Zuppa, AF | 1 |
| Hideta, K; Higasa, S; Hikasa, S; Kimura, T; Nishida, S; Sawada, A; Shimabukuro, S; Tanaka, K; Tokugawa, T; Yanai, M | 1 |
| Chen, X; Cheng, J; Feng, S; Han, K; Han, M; Liang, P; Liu, S; Lu, H; Wang, Y; Yuan, X; Zhao, J; Zhou, L | 1 |
| Arenas-Pinto, A; Berger, F; Mauss, S; Milinkovic, A | 1 |
| Imai, Y; Kouyama, JI; Mochida, S; Motoya, D; Naiki, K; Nakao, M; Nakayama, N; Sugawara, K; Tomiya, T; Tsuji, S; Uchida, Y; Uemura, H | 1 |
| Ajana, F; Bani-Sadr, F; Bouvet, E; Cotte, L; Galempoix, JM; Gantner, P; Hessamfar, M; Hustache-Mathieu, L; Lebrette, MG; Muret, P; Pellissier, G; Piroth, L; Rey, D; Rouveix, E; Simon, A; Souala, MF; Truchetet, F; Valin, N | 1 |
| Drak, D; Gracey, DM; O'Connor, CC; Templeton, DJ; Turner, D | 1 |
| Blennow, K; Das, M; Gisslen, M; Hermansson, L; Makadzange, T; McCallister, S; Nilsson, S; Price, RW; Yilmaz, A; Zetterberg, H | 1 |
| Eron, JJ; Esser, S; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Podzamczer, D; Rockstroh, J; Van Landuyt, E; Vandekerckhove, L | 1 |
| Bhatia, R; Rizza, S; Temesgen, Z; Zeuli, J | 1 |
| Di Perri, G; Shafran, SD | 1 |
| Cain, CM; Dobek, G; Grasperge, B; Hope, T; Karunakaran, D; Kiser, PF; Marzinke, M; Pearson, E; Peet, MM; Qiu, J; Simpson, SM; Su, JT; Sung, S; Tfaily, EB; Veazey, R; Watrous, D; Widanapathirana, L | 1 |
| Benson, C; Bolan, R; Crofoot, G; Dunn, K; Gathe, J; Huhn, GD; Luo, D; Nettles, RE; Ramgopal, M; Simonson, RB | 1 |
| Chuang, YC; Hung, CC; Kuo, PH; Liu, WC; Sun, HY; Wu, PY | 1 |
| Jaeger, H; Jonsson-Oldenbuettel, C; Noe, S | 1 |
| Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; Gartland, MJ; Nascimento, MC; Osiyemi, O; Pappa, KA; Portilla Sogorb, J; Routy, JP; Smith, KY; Tenorio, AR; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B | 1 |
| Daskalakis, DC; Feinberg, J; Krakower, DS; Marcus, JL | 2 |
| Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okada, M; Osawa, L; Sekiguchi, S; Shimizu, T; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Watakabe, K; Yamashita, K; Yasui, Y | 1 |
| Álvarez, M; Chueca, N; Collado, A; de Salazar, A; Fernández, JM; Fernández-Fuertes, E; García, F; Lozano, AB | 1 |
| Chen, Y; Lu, Y; Tao, X; Zhang, L; Zhou, Y | 1 |
| Applin, S; Asmuth, DM; Cox, S; Das, M; Goldstein, D; Guyer, B; Haubrich, RH; Hinestrosa, F; Huhn, GD; Jain, MK; Jiang, S; Nguyen-Cleary, T; Piontkowsky, D; Ramgopal, M; Rossaro, L; Ryu, JH; Slim, J | 1 |
| Chen, YS; German, P; Kearney, BP; Ling, KHJ; Ma, L; Majeed, SR; Tarnowski, T; Xiao, D; Zhang, T; Zhao, Y | 1 |
| Badowski, ME; Biagi, MJ; Chiampas, TD; Michienzi, SM; Patel, MC; Schriever, CA; Young, JD | 1 |
| Boesecke, C; Piduhn, H; Rockstroh, JK; Schlabe, S; Schwarze-Zander, C; Stoffel-Wagner, B; Strassburg, CP; Wasmuth, JC | 1 |
| Mak, LY | 1 |
| Agarwal, K; Ahn, SH; Bae, H; Buti, M; Chan, HLY; Chen, CY; Chuang, WL; Flaherty, JF; Fung, S; Gaggar, A; Lampertico, P; Lau, A; Lim, YS; Liu, Y; Ma, X; Ramji, A; Subramanian, GM; Suri, V; Tak, WY; Tam, E; Tan, SK; Trinh, H; Wu, G; Yoon, SK | 1 |
| Chen, HP; Chou, RY; Guo, JY; Tai, CC | 1 |
| Brooks, KM; Dooley, KE; Eke, AC; Gebreyohannes, RD; Mirochnick, M; Sheffield, JS | 1 |
| Armstrong, WS; Del Rio, C | 1 |
| Bernasconi, E; Calmy, A; Cavassini, M; Furrer, H; Fux, CA; Günthard, HF; Kovari, H; Ledergerber, B; Rauch, A; Schmid, P; Stöckle, M; Surial, B; Wandeler, G | 1 |
| Berruti, M; Briano, F; Di Biagio, A; Taramasso, L | 1 |
| Kumada, T; Miyake, N; Tada, T; Tanaka, J; Toyoda, H; Yasuda, S | 1 |
| Hooi, B; Leungsuwan, S; Myint, KS | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Takahashi, K | 1 |
| Barco, EA; Cotter, AG; Feeney, E; Lacey, A; Lambert, JS; Macken, A; Mallon, PW; Muldoon, E; Savinelli, S; Sheehan, G; Tinago, W | 1 |
| Agrahari, V; Banga, AK; Clark, MR; Doncel, GF; Gao, X; Jiang, Y; Peet, MM; Singh, ON; Zhang, W | 1 |
| Anderson, J; Baker, JV; Fletcher, CV; Jorstad, S; Mykris, T; Podany, AT; Schacker, TW; Thorkelson, A; Winchester, LC | 1 |
| Danziger, J; Morales, A | 1 |
| Bermejo-Vicedo, T; Gramage-Caro, T; Montero-Llorente, B; Rodríguez-Sagrado, MÁ; Vélez-Díaz-Pallarés, M | 1 |
| André-Garnier, E; Charpentier, C; Ferré, V; Hingrat, QL; Leducq, V; Malet, I; Marcelin, AG; Peytavin, G; Raffi, F; Reliquet, V; Rodallec, A | 1 |
| Hill, A; Venter, WDF | 1 |
| Panagopoulos, P; Papachristou, S; Papanas, N; Papazoglou, D; Petrakis, V; Terzi, I; Trypsianis, G | 1 |
| Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, J; Ibrahim, ME; Kiser, JJ; MaWhinney, S; McCallister, S; McHugh, C; Morrow, M; Yager, J | 1 |
| Gwenden, KN; Marzinke, MA; Parsons, TL | 1 |
| Brainard, D; McCallister, S | 1 |
| Alam, A; Charlton, MR; Cua, IHY; Dashtseren, B; Duger, D; Duy Cuong, D; Gani, RA; Hashmi, ZY; Hien, PTD; Jargalsaikhan, G; Kyi, KP; Lesmana, CRA; Madan, K; Mohamed, R; Naing, W; Payawal, DA; Piratvisuth, T; Rastogi, M; Salih, M; Saraf, N; Shukla, A; Singh, KR; Sollano, JD; Sukeepaisarnjaroen, W; Tanwandee, T; Thuy, PTT; Tun, KS; Win, KM | 1 |
| Acosta, R; Brainard, DM; Collins, SE; Liu, H; Luetkemeyer, AF; Martin, H; Rieger, A; Rockstroh, JK; Sax, PE; Trottier, B; Ward, D; Yazdanpanah, Y | 1 |
| Bremner, S; Bruce, C; Churchill, D; Geretti, AM; Iwuji, CC; Lambert, D; Orkin, C; Perry, N; To, Y; Waters, L | 1 |
| Cattaneo, D; Filice, C; Gervasoni, C; Riva, A | 1 |
| Spiegel, HML | 1 |
| Chang, SF; Chang, SY; Chen, GJ; Cheng, CY; Chuang, YC; Hsieh, MH; Huang, SH; Hung, CC; Lee, CH; Lee, YC; Lee, YL; Su, LS; Sun, HY; Tang, HJ; Tsai, HC | 1 |
| Anderson, PL; Blum, J; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Cendali, F; Choi, YJ; Gomez, J; Haas, H; Ibrahim, ME; Johnson, B; Kiser, JJ; MaWhinney, S; Morrow, M; Roon, L; Rowan, SE; Wyles, DL; Zheng, JH | 1 |
| Bloch, M; Gracey, DM; Heron, JE; Saunders, J; Vanguru, V | 1 |
| Cao, L; Chen, B; Chen, R; Ding, Y; Fan, J; Gan, W; Huang, Y; Lin, C; Liu, Y; Pan, CQ; Sheng, Q; Wang, S; Wang, Y; Zhu, L | 1 |
| Alonso-Vega, GG; Ferrández, JS; García, AL; García, TM; González, AO | 1 |
| Chang, S; Feierbach, B; Flaherty, J; Liu, Y; Martin, R; Mo, H | 1 |
| Béguelin, C; Bernasconi, E; Boillat-Blanco, N; Chave, JP; Doco-Lecompte, T; Fehr, J; Furrer, H; Günthard, HF; Rauch, A; Schmid, P; Stöckle, M; Surial, B; Walti, LN; Wandeler, G | 1 |
| Freedberg, KA; Horn, T; McCann, NC; Paltiel, AD; Walensky, RP | 1 |
| Bush, S; Das, M; Shreay, S; Ting, J | 1 |
| Chivite, I; Cottrell, ML; Domingo, P; Garcia, B; Imaz, A; Kashuba, ADM; Martinez-Picado, J; Morenilla, S; Negredo, E; Niubó, J; Podzamczer, D; Scévola, S; Schauer, A; Silva-Klug, A; Tiraboschi, JM; Urrea, V; Van Horne, B | 1 |
| Balcombe, SM; Hill, LA; Martin, TCS; Tang, ME | 1 |
| Djan, K; Dorsey, HG; Jnr, DA; Li, M; Musoff, C; Paintsil, E; Schoen, N; Zhou, L | 1 |
| Boffito, M; Emerson, M; Gazzard, B; Khawaja, AA; Lovell, AO; Nelson, M; Taylor, KA | 1 |
| Abrams, E; Akpomiemie, G; Arulappan, N; Chandiwana, N; Chersich, M; Clayden, P; Fairlie, L; Hill, A; Lalla-Edward, S; Maartens, G; Masenya, M; Mashabane, N; McCann, K; Moorhouse, M; Norris, S; Qavi, A; Serenata, C; Simmons, B; Sokhela, S; Venter, WDF; Vos, A | 1 |
| Wong, GL; Yip, TC | 1 |
| Gotham, D; Hill, A; Hughes, SL; McCann, K; Pepperrell, T; Pilkington, V; Pozniak, AL | 1 |
| Bini, T; Borsino, C; d'Arminio Monforte, A; De Bona, A; Gazzola, L; Marchetti, G; Mondatore, D; Tagliaferri, G | 1 |
| Burkholder, GA; Collier, AC; Crane, HM; Curtis, L; Delaney, JAC; Eron, JJ; Geng, E; Harding, BN; Henegar, C; Kitahata, MM; Lindström, S; Mathews, WC; Mayer, KH; Moore, RD; Nance, RM; Rodriguez, B; Ruderman, SA; Saag, MS; Van Wyk, J; Vannappagari, V; Whitney, BM; Willig, AL; Wood, BR | 1 |
| DeMarais, P; Max, B | 1 |
| Wood, BR | 1 |
| Babusis, D; Barouch, DH; Bekerman, E; Callebaut, C; Campigotto, F; Cihlar, T; Cox, S; Das, M | 1 |
| Cao, L; Huang, Y; Pan, CQ | 1 |
| Elmofti, Y; Gish, RG | 1 |
| Gandhi, M; Robles, G; Sauermilch, D; Starks, TJ | 1 |
| Achterfeld, A; Herzer, K; Rashidi-Alavijeh, J; Straub, K; Wedemeyer, H; Willuweit, K | 1 |
| Edmonston, D; Hemmersbach-Miller, M; Hung, A; Sinclair, M; Wyatt, C | 1 |
| Barr, E; Best, BM; Brooks, KM; Capparelli, EV; Chakhtoura, N; Cielo, M; Denson, K; Deville, JG; Espina, R; Febo, IL; George, K; Haubrich, R; Mirochnick, M; Momper, JD; Pinilla, M; Rooney, JF; Rungruengthanakit, K; Shapiro, DE; Smith, E; Stek, AM; Weinberg, A | 1 |
| Di Perri, G | 1 |
| Cheng, CY; Cheng, SH; Ho, MW; Huang, SH; Huang, YS; Hung, CC; Lee, CH; Lee, YT; Lin, SP; Liou, BH; Liu, CE; Lu, PL; Sun, HY; Tang, HJ; Tsai, HC; Yang, CJ | 1 |
| Ma, R; Tong, ZW; Xu, B; Zhang, Q; Zhang, YS; Zhao, CS; Zhao, RG | 1 |
| Hill, A; Shah, S | 1 |
| Daugherty, T; Goel, A; Kim, WR; Kwo, PY; Kwong, A; Mannalithara, A; Sripongpun, P | 1 |
| Baugh, B; De Meyer, S; Ghys, A; Jezorwski, J; Lathouwers, E; Mohsine, EG; Van Landuyt, E; Weinsteiger, S | 1 |
| Castagna, A; Esser, S; Haubrich, R; Llibre, JM; Margot, N; McNicholl, IR; Molina, JM; Perez-Valero, I; Piontkowsky, D; Pulido, F; Shao, Y; Temme, L | 1 |
| Chen, ZM; Cui, GL; Ji, F; Li, GM; Li, J; Li, W; Li, ZQ; Liang, HX; Liu, YM; Lv, J; Pan, YJ; Sun, CY; Wang, FS; Xu, JH; Yu, ZJ; Zeng, QL; Zhang, DW; Zhang, GF | 1 |
| Chen, G; Chen, SH; Fu, YM; Ji, D; Li, L; Li, ZB; Liu, Y; Niu, XX; Shao, Q; Wang, CY | 1 |
| Lai, J; Li, J; Li, X; Peng, L; Shu, X; Xie, C; Xie, J; Xu, W; Zhang, Y; Zhu, X | 1 |
| Baugh, B; Brown, K; El Ghazi, M; Huhn, GD; Jezorwski, J; Lathouwers, E; Mussini, C; Spinner, CD; Van Landuyt, E; Wilkin, A | 1 |
| Abdel-Razeq, SA; Nasr, ZA; Said, NS | 1 |
| Ait-Khaled, M; Ajana, F; Jones, B; Nascimento, MC; Santos, J; Scholten, S; Smith, DE; Tenorio, AR; van Wyk, J; Wohlfeiler, M; Wright, J; Wynne, B | 1 |
| Jain, MK; Kshirsagar, O; Niu, B; Thamer, M; Therapondos, G; Wong, RJ | 1 |
| Mesplède, T | 1 |
| Arai, T; Asai, A; Atsukawa, M; Cheung, R; Chien, N; Chuma, M; Dang, H; Fukunishi, S; Henry, L; Hoang, J; Huang, DQ; Ishikawa, T; Landis, C; Le, RH; Leong, J; Lim, SG; Liu, J; Maeda, M; Nguyen, MH; Quek, SXZ; Senoo, T; Takaguchi, K; Thin, KN; Toyoda, H; Tran, S; Trinh, HN; Uojima, H; Watanabe, T; Yasuda, S; Yokohama, K | 1 |
| Hatakeyama, S; Kanda, N; Mieno, M; Okamoto, K; Okumura, H; Sakashita, K; Sasahara, T | 1 |
| Bernasconi, E; Calmy, A; Cavassini, M; Furrer, H; Günthard, HF; Ledergerber, B; Mugglin, C; Rauch, A; Schmid, P; Stöckle, M; Surial, B; Tarr, PE; Wandeler, G | 1 |
| Brahmania, M; Coffin, CS; Conway, B; Cooper, C; Doucette, K; Farag, MS; Fung, S; Hansen, BE; Haylock-Jacobs, S; Janssen, HLA; Ramji, A; Sebastiani, G; Tam, E; Tsoi, K; Wong, A; Wong, P | 1 |
| Bonomini, M; Di Liberato, L; Piscitani, L; Pontolillo, M; Ucciferri, C; Vecchiet, J | 1 |
| Chan, HL; Hui, VW; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Butcher, L; Davidson, AM; Johnson, M; Joshi, SR; Lataillade, M; Min, S; Pene Dumitrescu, T; Webster, L; Xu, J; Zhan, J; Zimmerman, E | 1 |
| Lake, JE; Trevillyan, J | 1 |
| Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L | 1 |
| Breslin, PAS; Choma, K; Christensen, CM; Flammer, LJ; Jiang, P; Margolskee, RF; Ozdener, MH; Rawson, NE; Rivers, N; Schwiebert, E; Streiff, J; Wang, Y; Xi, R | 1 |
| Beyer, AP; Brunet, L; Fusco, GP; Fusco, JS; Hsu, RK; Mallon, PW; Mounzer, KC; Prajapati, G; Wohlfeiler, MB | 1 |
| Bowen, AC; Campbell, AJ; Yeoh, DK | 1 |
| Acosta, RK; Brainard, D; Chang, S; Chen, GQ; Collins, SE; Huang, H; Martin, H; Martin, R; Wang, X; White, KL | 1 |
| Bernasconi, E; Calmy, A; Cavassini, M; Kovari, H; Ledergerber, B; Rauch, A; Schmid, P; Surial, B; Tarr, PE; Wandeler, G | 1 |
| Baum, MM; Demkovich, ZR; Diana, F; Dobard, C; Feldman, PL; Garcia-Lerma, JG; Grattoni, A; Gunawardana, M; Ho, DK; Hope, TJ; Massud, I; Milad, M; Moss, JA; Pons-Faudoa, FP; Roller, S; Romano, JW; Srinivasan, S; van der Straten, A; Veazey, RS; Zane, D | 1 |
| Byun, KS; Choi, J; Gwak, GY; Kim, JH; Kim, YJ; Kwon, SY; Lee, HC; Lee, YS; Lim, YS; Yoo, BC | 1 |
| Bae, SH; Brunetto, M; Çelen, MK; Chang, TT; Coffin, CS; Flaherty, JF; Gaggar, A; Gane, EJ; Mo, S; Nguyen, MH; Pan, CQ; Seto, WK; Tan, SK; Thompson, A | 1 |
| Gandhi, M; Glidden, DV; Johnson, KA; Okochi, H; Spinelli, M | 1 |
| Dunn, K; Hardy, H; Kassam, PT; Luo, D; Rogers, R; Seyedkazemi, S; Sheng, S; Simonson, RB | 1 |
| Gutiérrez-Lorenzo, M; Rubio-Calvo, D; Urda-Romacho, J | 1 |
| Ikeda, M; Moriya, K; Okamoto, K; Okugawa, S; Wakabayashi, Y; Yanagimoto, S | 1 |
| Bernstein, DE; Fried, MW; Lok, AS; Mospan, AR; Schiff, ER; Smith, CI; Trinh, HN; Zink, RC | 1 |
| Alrubayyi, A; Burns, F; Fisher-Pearson, N; Gilson, R; Griffith, SA; Gupta, RK; Kinloch, S; McCoy, LE; Muir, L; Pellegrino, P; Peppa, D; Rees-Spear, C; Rowland-Jones, S; Touizer, E; Waters, L | 1 |
| Bachelard, A; Chalal, L; Damond, F; Descamps, D; Ghosn, J; Isernia, V; Landman, R; Le Gac, S; Peytavin, G; Vallois, D; Yazdanpanah, Y | 1 |
| Chen, T; Chen, Y; Fu, M; Fu, S; Gao, Z; He, Y; Hu, C; Li, J; Liu, J; Yan, T; Yang, Y; Zhang, R; Zhao, Y; Zhou, M | 1 |
| Buti, M; Esteban, R; Marcos-Fosch, C | 1 |
| Cai, C; Dong, S; Hu, W; Jia, L; Li, Q | 1 |
| Bamoulid, J; Clairet, AL; Davani, S; Ducloux, D; Flammang, M; Lagoutte-Renosi, J; Lepiller, Q; Muret, P; Royer, PY | 1 |
| Alessi, T; Feldman, PL; Felx, M; Jain, R; Roller, S; Shelton, J; Singh, R; Wang, Y; Yang, B; Zane, D | 1 |
| Asmuth, DM; Baeten, JM; Brainard, DM; Brunetta, JM; Carter, C; Cox, S; Das, M; Ebrahimi, R; Gilson, R; Henry, K; Kintu, A; Kronborg, G; Ogbuagu, O; Podzamczer, D; Ruane, PJ; Salazar, LC; Shao, Y; Spinner, CD; Whitlock, G; Wohl, D | 1 |
| Asif, S; Baxevanidi, E; Chandiwana, N; Fairlie, L; Hill, A; Masenya, M; Serenata, C; Sokhela, S; Venter, WDF | 1 |
| Duan, M; Gu, Y; Li, B; Liu, D; Liu, Q; Liu, X; Liu, Z; Ma, Q; Wang, Y; Wei, Y | 1 |
| Carneiro, PB; D'Angelo, AB; Grov, C; Johnson, J; Westmoreland, DA | 1 |
| Andreatta, K; Berger, D; Blair, C; Brainard, DM; Brar, I; Collins, SE; Hagins, D; Hileman, CO; Kumar, P; Martin, H; McDonald, C; Osiyemi, O; Ramgopal, MN; Saag, M; Wurapa, AK | 1 |
| Ahn, SH; Cho, YY; Kim, BK; Kim, DY; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Park, SY | 2 |
| Lai, J; Li, X; Peng, L; Wang, L; Wu, L; Xie, C; Zhang, Y; Zhu, X | 1 |
| Avihingsanon, A; Avihingsanon, Y; Gatechompol, S; Iampenkhae, K; Surintrspanont, J; Udomkarnjananun, S; Ueaphongsukkit, T | 1 |
| Bernstein, A; Saber, S; Siegel, M; Sjaarda, A; Sparks, A | 1 |
| Darnell, J; Hill, LA; Jain, S; Karris, MY; Qin, H; Reynolds, T; Sun, X | 1 |
| Agrati, C; Antinori, A; Cicalini, S; D'Avolio, A; De Nicolò, A; Tempestilli, M | 1 |
| Anderson, PL; Brooks, KM; Bushman, L; Castillo-Mancilla, JR; Ibrahim, M; Kiser, JJ; MaWhinney, S; Morrow, M; Nemkov, C; Peterson, S; Yager, JL | 1 |
| Darcis, G; Fombellida, K; Frippiat, F; Lecomte, M; Léonard, P; Maes, N; Meuris, C; Moutschen, M; Paquot, N; Plum, PE; Sauvage, AS; Uurlings, F; Vaira, D | 1 |
| Ajana, F; Brainard, D; Chuck, SK; Collins, SE; Gandhi-Patel, B; Kityo, C; Koenig, E; Liu, Y; Makadzange, T; McNicholl, I; Natukunda, E; Orkin, C; Pikora, C; Wang, H; Wei, X; White, K | 1 |
| Barbini, B; Burling, K; Campbell, L; Cromarty, B; Hamzah, L; Johnson, M; Jones, R; Post, FA; Samarawickrama, A; Williams, D; Winston, A | 1 |
| Alnouti, Y; Bade, AN; Cobb, DA; Cohen, SM; Deodhar, S; Edagwa, B; Gautam, N; Gendelman, HE; McMillan, J; Shetty, BLD; Smith, N | 1 |
| Beyer, A; Brunet, L; Fusco, GP; Fusco, JS; Mallon, P; Prajapati, G; Wohlfeiler, MB | 1 |
| Huang, X; Kallakury, BV; Kim, YW; Korolowicz, KE; Lee, KP; Li, B; Menne, S; Park, S; Suresh, M; Yon, C | 1 |
| Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Nguyen, MH; Trinh, S; Yeh, ML; Yu, ML | 1 |
| Gao, LY; Hu, Y; Huang, XJ; Ma, P; Wu, H; Wu, Y; Xia, H; Yan, ZF | 1 |
| Lyu, J; Pan, L; Teng, J; Wu, H; Zhang, F; Zhang, M; Zhu, C | 1 |
| Jeong, S; Kim, HI; Shin, HP | 1 |
| Bazzi, R; Roa, PE | 1 |
| Ahn, SH; Chon, HY; Kim, SU; Kim, YJ; Lee, JH; Sinn, DH; Yoon, JH | 1 |
| Cheng, CN; Chuang, YC; Hung, CC; Kuo, CH; Lin, KY; Lin, SW; Lin, YJ; Lin, YT; Liou, BH; Liu, WC; Sun, HY | 1 |
| Alba Alejandre, I; Bukkems, VE; Burger, D; Colbers, A; Garcia, C; Hidalgo Tenorio, C; Konopnicki, D; Lambert, JS; Necsoi, C; Richel, O; Te Brake, LHM; van der Meulen, E; van Hulzen, A; Weiss, F | 1 |
| Bon, I; Borderi, M; Calza, L; Colangeli, V; Lazzarotto, T; Miani, T; Nuti, B; Viale, P | 1 |
| Abe, K; Goto, T; Imamura, J; Ito, T; Kamio, S; Kondo, A; Obara, T; Sato, H; Takahashi, N | 1 |
| Hideta, K; Higasa, S; Hikasa, S; Kimura, T; Sawada, A; Shimabukuro, S; Tanaka, K; Tokugawa, T; Yanai, M | 1 |
| Acosta, R; Andreatta, K; Chang, S; D'Antoni, ML; Martin, H; Martin, R; White, KL | 1 |
| Li, J; Shi, J; Tran, L; Wang, X; Xiao, J; Zhu, HJ | 1 |
| Hirota, T; Ieiri, I; Ito, S; Muto, M; Taya, Y; Watanabe, E; Yanai, M | 1 |
| Jeong, J; Jung, SW; Park, EJ; Park, NH; Shin, JW | 1 |
| Gelman, M; Holmes, J; Kraft, J; Mayer, KH; Melbourne, K; Mimiaga, MJ | 1 |
| Abdool Karim, Q; Abdool Karim, S; Baum, MM; Baxter, C; Gengiah, TN; Hankins, C; Harkoo, I; Maharaj, B; Mansoor, L; Moss, JA; Pozzetto, B; Radebe, P; Samsunder, N; Zuma, NY | 1 |
| Cressey, TR; Dossantos, S; Drain, PK; Niu, X; Sandlin, RD; Sevenler, D; Toner, M | 1 |
| Ambrosioni, J; Berrocal, L; Blanco, JL; Chivite, I; de la Mora, L; de Lazzari, E; González-Cordón, A; Inciarte, A; Laguno, M; Leal, L; Mallolas, J; Martinez, E; Martínez-Rebollar, M; Miró, JM; Rojas Liévano, J; Torres, B; Ugarte, A | 1 |
| Ito, T; Kumada, T; Tanaka, J; Toyoda, H; Yasuda, S | 1 |
| Abiko, S; Kawagishi, N; Kimura, M; Kinoshita, K; Kitagataya, T; Maehara, O; Miyamoto, S; Morikawa, K; Nakai, M; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shigesawa, T; Sho, T; Suda, G; Sugiura, R; Suzuki, K; Yamada, R; Yamamoto, Y | 1 |
| Amagase, H; Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Ichiki, Y; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Kuniyoshi, M; Morita, C; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Sugimoto, R; Takahashi, K; Yamashita, N | 2 |
| Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; George, N; Leone, P; Osiyemi, O; Pappa, KA; Portilla, J; Routy, JP; Smith, KY; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B | 1 |
| Barday, Z; Geragotellis, A; Naicker, V; Patel, S; Sanglay, L; Sonderup, M; Spearman, CW; Wearne, N | 1 |
| Agarwal, K; Flaherty, JF; Fung, S; Gordon, SC; Hou, J; Kao, JH; Kurosaki, M; Lampertico, P; Lim, YS; Seto, WK; Yee, LJ; Zhao, Y | 1 |
| Imai, Y; Kouyama, JI; Mochida, S; Naiki, K; Nakao, M; Nakayama, N; Sugawara, K; Tomiya, T; Tsuji, S; Uchida, Y; Uemura, H; Yamada, S | 1 |
| Lin, HY; Tseng, TC | 1 |
| Kamiya, K; Kishimoto, M; Komine, M; Kuwahara, A; Morimoto, N; Ohtsuki, M; Sugai, J | 1 |
| Barr, E; Best, BM; Brooks, KM; Browning, R; Capparelli, EV; Chakhtoura, N; Deville, JG; Febo, IL; George, K; Knowles, K; Mirochnick, M; Paul, ME; Pinilla, M; Rungruengthanakit, K; Shapiro, DE; Stek, AM | 1 |
| Choi, J; Choi, WM; Kim, KM; Lee, D; Lee, HC; Lim, J; Lim, YS; Shim, JH | 1 |
| Acosta, R; Andreatta, K; Blair, C; Chang, S; Collins, SE; D'Antoni, ML; Daar, ES; Gallant, J; Hagins, D; Liu, H; Martin, H; Martin, R; McNicholl, I; Molina, JM; Sax, PE; White, KL | 1 |
| Alessandri-Gradt, E; Martin, C; Plantier, JC; Unal, G | 1 |
| Cheng, AK; Lee, WA | 1 |
| Bookstaver, PB; Clary, JC; Derrick, C; Drummond, M; Rowe, SM; Sanasi, K | 1 |
| Baum, MM; Beliveau, M; Buser, C; Caprioli, RM; Castonguay, AE; Gallay, PA; Gunawardana, M; Hendrix, CW; Kuo, J; Marzinke, MA; Moss, JA; Remedios-Chan, M; Reyzer, ML; Sanchez, D; Trinh, M; Tuck, M; Webster, P; Webster, S | 1 |
| Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A | 1 |
| Bernardino, JI; de Gea Grela, A; Martín Carbonero, L; Micán, R; Ramos, L; Valencia, ME | 1 |
| Cerankowski, J; Keith, SW; Schafer, JJ; Shimada, A; Walshe, C; Zimmerman, M | 1 |
| Aho, I; Kauppinen, KJ; Sutinen, J | 1 |
| Agorastou, P; Dalekos, GN; Deutsch, M; Elefsiniotis, I; Gatselis, N; Goulis, J; Kapatais, A; Karaoulani, T; Karatapanis, S; Kranidioti, H; Kyriazidou, A; Manesis, E; Manolakopoulos, S; Mimidis, K; Mylopoulou, T; Papatheodoridi, M; Papatheodoridis, GV; Samonakis, D; Sevastianos, V; Triantos, C; Vasiliadis, T; Zisimopoulos, K | 1 |
| Chen, YC; Chien, RN; Hsu, CW; Tai, DI | 1 |
| Bossolasco, S; Bruzzesi, E; Carini, E; Castagna, A; Chiurlo, M; Galli, L; Gianotti, N; Lazzarin, A; Mancusi, D; Mastrangelo, A; Nozza, S; Poli, A; Ranzenigo, M; Spagnuolo, V; Termini, R | 1 |
| Chang, HY; Chang, SF; Chang, SY; Chen, GJ; Chen, LY; Chuang, YC; Hsieh, SM; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Liu, WD; Luo, YZ; Sheng, WH; Su, YC; Sun, HY; Wu, PY | 1 |
| Parveen, S; Shah, A; Singh, J; Tiwari, A | 1 |
| Andreoni, M; Antinori, A; Armenia, D; Berno, G; Bertoli, A; Borghi, V; Buonomini, A; Ceccherini-Silberstein, F; Cicalini, S; Forbici, F; Gagliardini, R; Gennari, W; Lanini, S; Latini, A; Malagnino, V; Mussini, C; Perno, CF; Santoro, MM; Sarmati, L; Teti, E | 1 |
| Kumar, M | 1 |
| Gane, E; Kashuba, A; Levy, MT | 1 |
| Lee, MH | 1 |
| Chen, J; Hu, X; Li, Q; Li, R; Yuan, G; Zang, M | 1 |
| Papatheodoridis, GV | 1 |
| Chen, CH; Tseng, TN | 1 |
| Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU; Lee, HW; Lee, JI | 1 |
| Chen, EQ; Wang, ML | 1 |
| Ogawa, E | 1 |
| Liu, W; Yan, B; Yu, S | 1 |
| Cao, T; He, Y; Jia, X; Ju, B; Liu, J; Liu, X; Peng, Q; Rao, M; Song, Y; Sun, L; Wang, H; Wang, S; Xu, L; Zhang, H; Zhang, L; Zhang, Q; Zhao, F; Zhou, J; Zhou, Y | 1 |
| Akahane, T; Inoue, J; Iwata, T; Kisara, N; Kobayashi, T; Masamune, A; Ninomiya, M; Onuki, M; Sano, A; Sato, K; Sato, S; Tsuruoka, M | 1 |
| Chao, Y; Hou, MC; Huang, YH; Lan, KH; Lee, IC; Li, CP; Lin, HC; Su, CW | 1 |
| Assoumou, L; Bachelard, A; Benalycherif, A; Charpentier, C; Descamps, D; Donadille, C; Duvivier, C; El Mouhebb, M; Ghosn, J; Isernia, V; Lacombe, K; Landman, R; Mora, M; Peytavin, G; Spire, B | 1 |
| Boyd, A; Reiss, P; Van der Valk, M; Verburgh, ML; Wit, FWNM | 1 |
| Angioni, G; Attala, L; Bandera, A; Bargiacchi, O; Bonfanti, P; Cascio, A; Cenderello, G; De Socio, GV; Di Biagio, A; Falasca, K; Maggi, P; Maurizio Celesia, B; Menzaghi, B; Orofino, G; Pellicanò, GF; Piconi, S; Ricci, E; Sarchi, E; Simeone, F; Squillace, N; Taramasso, L; Valsecchi, L | 1 |
| Ardila, F; Bernal, E; Casadellà, M; Curran, A; Echeverria, P; Estrada, V; Fanciulli, C; Gutierrez, A; Hernández, C; Hidalgo-Tenorio, C; Imaz, A; Knobel, H; Lagarde, M; Lopez-Lirola, A; Macias, J; Masiá, M; Montero-Alonso, M; Morano, L; Navarro-Alcaraz, A; Parera, M; Podzamczer, D; Portilla, J; Prieto, P; Rigo, R; Rivero, A; Troya, J; Valencia, E; Vivancos, MJ | 1 |
43 review(s) available for alanine and gs-7340
| Article | Year |
|---|---|
Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Drug Stability; Fanconi Syndrome; HIV Infections; HIV-1; Humans; Kidney; Prodrugs; Tenofovir; Virus Replication | 2016 |
The role of tenofovir alafenamide in future HIV management.
Topics: Adenine; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Prodrugs; Tenofovir; Treatment Outcome | 2016 |
Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
Topics: Adenine; Alanine; Antiviral Agents; HIV Infections; Humans; Tenofovir | 2016 |
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Quinolones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Renal effects of novel antiretroviral drugs.
Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Proteinuria; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency, Chronic; Tenofovir | 2017 |
Tenofovir Alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Bone Density; Female; HIV Infections; HIV-1; Humans; Prodrugs; Reverse Transcriptase Inhibitors; Tablets; Tenofovir | 2016 |
The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; HIV-1; Humans; RNA, Viral; Tenofovir; Treatment Outcome | 2016 |
Tenofovir alafenamide (Vemlidy) for hepatitis B.
Topics: Adenine; Alanine; Animals; Antiviral Agents; Clinical Trials as Topic; Hepatitis B; Humans; Tenofovir | 2017 |
Tenofovir alafenamide fumarate for the treatment of HIV infection.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Viral; HIV Infections; Humans; Tenofovir | 2016 |
Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Male; Prodrugs; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2017 |
Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings.
Topics: Adenine; Alanine; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Rifampin; Tenofovir | 2017 |
Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Alanine; Animals; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir; Time Factors | 2017 |
Tenofovir Alafenamide: A Review in Chronic Hepatitis B.
Topics: Adenine; Adolescent; Adult; Alanine; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Randomized Controlled Trials as Topic; Tenofovir | 2017 |
Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
Topics: Adenine; Age Factors; Alanine; Antiviral Agents; Bone Density; Clinical Decision-Making; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney; Male; Osteoporosis; Patient Safety; Pregnancy; Renal Insufficiency; Risk Factors; Tenofovir; Treatment Outcome | 2017 |
Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy.
Topics: Adenine; Alanine; Antiviral Agents; Clinical Trials as Topic; Hepatitis B, Chronic; Humans; Molecular Conformation; Tenofovir | 2017 |
Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections.
Topics: Adenine; Alanine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2018 |
Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug.
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Drug Interactions; Glomerular Filtration Rate; Hepatitis B; HIV Infections; Humans; Kidney Diseases; Pre-Exposure Prophylaxis; Prodrugs; Tenofovir | 2018 |
Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Dose-Response Relationship, Drug; Hepatitis B, Chronic; Humans; Prodrugs; Renal Insufficiency; Tenofovir | 2018 |
Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.
Topics: Adenine; Administration, Oral; Alanine; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Guanine; Hepatitis B, Chronic; Humans; Nucleosides; Randomized Controlled Trials as Topic; Tenofovir; Time Factors; Treatment Outcome | 2018 |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Darunavir; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Genes, MDR; HIV Infections; HIV-1; Humans; Renal Reabsorption; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2018 |
Tolerability of Current Antiretroviral Single-Tablet Regimens
Topics: Adenine; Alanine; Anti-Retroviral Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; Humans; Tablets; Tenofovir | 2018 |
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Protease Inhibitors; Randomized Controlled Trials as Topic; Tenofovir | 2018 |
An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents.
Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Child; Cobicistat; Emtricitabine; HIV Infections; Humans; Quinolones; Tablets; Tenofovir; United States; United States Food and Drug Administration | 2019 |
Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications.
Topics: Adenine; Alanine; Amides; Animals; Anti-HIV Agents; Drug Combinations; Drug Interactions; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Piperazines; Pyridones; Tablets; Tenofovir | 2019 |
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans; Incidence; Male; Middle Aged; Renal Insufficiency; Tenofovir; Young Adult | 2019 |
Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide.
Topics: Adenine; Age Factors; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Comorbidity; Disease Management; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Life Style; Tenofovir; Treatment Outcome | 2019 |
Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline.
Topics: Adenine; Administration, Cutaneous; Administration, Oral; Alanine; Contraceptive Devices, Female; Delayed-Action Preparations; Deoxyadenosines; Emtricitabine; Female; HIV Infections; Humans; Incidence; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2019 |
Tenofovir Urine Assay to Monitor Adherence to HIV Pre-exposure Prophylaxis.
Topics: Alanine; Anti-HIV Agents; Chromatography, High Pressure Liquid; HIV Infections; Humans; Mass Spectrometry; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Bictegravir, a novel integrase inhibitor for the treatment of HIV infection.
Topics: Adenine; Alanine; Amides; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; Humans; Piperazines; Pyridones; Tenofovir | 2019 |
Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; HIV Infections; HIV Seropositivity; HIV-1; Humans; Kidney; Randomized Controlled Trials as Topic; Tablets; Tenofovir | 2020 |
Severe acute hypokalaemia associated with piperacillin/tazobactam in an HIV-infected patient under antiretroviral therapy with tenofovir alafenamide: case report and literature review.
Topics: Acquired Immunodeficiency Syndrome; Alanine; Antiviral Agents; Humans; Hypokalemia; Male; Middle Aged; Piperacillin, Tazobactam Drug Combination; Tenofovir | 2020 |
Tenofovir alafenamide use in pregnant and lactating women living with HIV.
Topics: Adenine; Alanine; Anti-HIV Agents; Female; HIV Infections; Humans; Lactation; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Tenofovir | 2020 |
An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia.
Topics: Alanine; Antiviral Agents; Asia; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Randomized Controlled Trials as Topic; Tenofovir | 2020 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; HIV Infections; Humans; Randomized Controlled Trials as Topic; Tenofovir | 2020 |
Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy.
Topics: Alanine; Anti-HIV Agents; Diabetes Mellitus; HIV Infections; HIV Integrase Inhibitors; Humans; Metabolic Syndrome; Tenofovir; Weight Gain | 2021 |
Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; Fumarates; HIV Infections; HIV-1; Humans; Male; Tenofovir | 2021 |
Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV.
Topics: Alanine; Anti-HIV Agents; HIV Infections; HIV Integrase Inhibitors; Humans; Tenofovir; Weight Gain | 2021 |
Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting.
Topics: Adenine; Adolescent; Alanine; Animals; Anti-HIV Agents; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir dis
Topics: Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Obesity; Oxazines; Piperazines; Pregnancy; Pregnancy Outcome; Pyridones; Tenofovir | 2021 |
Tenofovir alafenamide nephrotoxicity: a case report and literature review.
Topics: Adenine; Alanine; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Middle Aged; Tenofovir | 2021 |
Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections.
Topics: Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Hepatitis B; History, 20th Century; History, 21st Century; HIV; HIV Infections; Humans; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir | 2021 |
Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data.
Topics: Adenine; Aged; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Piperazines; Pyridones; Tenofovir; Viral Load | 2022 |
72 trial(s) available for alanine and gs-7340
| Article | Year |
|---|---|
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Area Under Curve; Dose-Response Relationship, Drug; Fatigue; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nausea; Organophosphates; Organophosphonates; RNA, Viral; Single-Blind Method; Statistics, Nonparametric; Tenofovir; Viral Load; Young Adult | 2013 |
Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Anti-HIV Agents; Area Under Curve; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Plasma; Prodrugs; Tenofovir; Young Adult | 2014 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte Count; Cholesterol; Creatinine; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Prodrugs; Proteinuria; RNA, Viral; Tenofovir; United States | 2014 |
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.
Topics: Adenine; Adult; Alanine; Antiviral Agents; DNA, Viral; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Time Factors; Treatment Outcome; Young Adult | 2015 |
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; RNA, Viral; Tenofovir | 2015 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; Headache; HIV Infections; Humans; Kidney; Male; Nausea; Organophosphonates; Quinolones; Respiration Disorders; Sleep Initiation and Maintenance Disorders; Tenofovir; Thiazoles; Treatment Outcome; Viral Load | 2015 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Tenofovir; Viral Load | 2016 |
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
Topics: Adenine; Alanine; Albuminuria; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Proteinuria; Quinolones; RNA, Viral; Tenofovir | 2016 |
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Tenofovir; Young Adult | 2016 |
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Tenofovir | 2016 |
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Coinfection; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hepatitis B; HIV Infections; Humans; Male; Middle Aged; Quinolones; Tenofovir; Treatment Outcome | 2016 |
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Comorbidity; Female; HIV Infections; HIV-1; Humans; Inflammation Mediators; Male; ROC Curve; Tenofovir | 2016 |
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Child; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lost to Follow-Up; Male; Quinolones; RNA, Viral; South Africa; Tablets; Tenofovir; Thailand; Uganda; United States; Viral Load | 2016 |
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Topics: Adenine; Adolescent; Adult; Alanine; Amides; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load; Young Adult | 2017 |
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-i
Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Middle Aged; Rilpivirine; Tenofovir | 2017 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Rilpivirine; Tenofovir | 2017 |
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults.
Topics: Adenine; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; HIV Infections; HIV-1; Humans; Middle Aged; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Emtricitabine; HIV Infections; Humans; Middle Aged; Quinolones; Tenofovir; Treatment Outcome; United States | 2017 |
Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues.
Topics: Adenine; Adult; Alanine; Cervix Uteri; Drug Administration Schedule; Epithelial Cells; Female; Gastrointestinal Tract; Humans; Intestinal Mucosa; Leukocytes, Mononuclear; Middle Aged; Mucous Membrane; Organophosphates; Pre-Exposure Prophylaxis; Rectum; Tenofovir; Tissue Distribution; Vagina; Young Adult | 2017 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2016 |
Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects.
Topics: Adenine; Administration, Oral; Adult; Alanine; Anti-HIV Agents; Asian People; Breakfast; Cobicistat; Cross-Over Studies; Dietary Proteins; Dietary Supplements; Emtricitabine; Fasting; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Quinolones; Tenofovir | 2018 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Internationality; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult | 2017 |
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Double-Blind Method; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult | 2017 |
Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
Topics: Adenine; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Cobicistat; Drug Combinations; Drug Substitution; Emtricitabine; HIV Infections; HIV-1; Humans; Kidney; Quinolones; RNA, Viral; Tenofovir; Treatment Outcome | 2018 |
Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Protease Inhibitors; Quinolones; RNA, Viral; Tenofovir | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Female; Glomerular Filtration Rate; Hepatitis B; Hepatitis B e Antigens; Humans; Male; Middle Aged; Tenofovir; Young Adult | 2018 |
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph
Topics: Adenine; Adult; Aged; Alanine; Amides; Anti-Retroviral Agents; Drug Substitution; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Piperazines; Protease Inhibitors; Pyridones; Sustained Virologic Response; Tenofovir; Viral Load; Young Adult | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; Europe; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Piperazines; Pyridones; Tenofovir; United States; Young Adult | 2018 |
Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.
Topics: Adenine; Adult; Alanine; Area Under Curve; Biological Availability; Cobicistat; Cross-Over Studies; Darunavir; Drug Combinations; Fasting; Female; Food; Humans; Male; Middle Aged; Tablets; Tenofovir; Therapeutic Equivalency; Young Adult | 2019 |
Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolones; RNA, Viral; Semen; Semen Analysis; Tenofovir | 2019 |
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-infer
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2019 |
Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.
Topics: Adenine; Adult; Aged; Alanine; Antiviral Agents; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir | 2019 |
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Substitution; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sustained Virologic Response; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Topics: Adenine; Adult; Alanine; Amides; Amino Acid Substitution; Anti-HIV Agents; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Genotype; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; RNA, Viral; Sustained Virologic Response; Tenofovir | 2019 |
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Darunavir; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sustained Virologic Response; Tablets; Tenofovir; Viral Load; Young Adult | 2019 |
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a m
Topics: Adenine; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Tablets; Tenofovir | 2019 |
Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; CD4 Lymphocyte Count; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Young Adult | 2019 |
Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.
Topics: Adenine; Alanine; Creatinine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Tubules, Proximal; Linear Models; Male; Middle Aged; Retinol-Binding Proteins; Tenofovir; Treatment Outcome; United Kingdom | 2020 |
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Quinolones; Tablets; Tenofovir | 2020 |
Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Central Nervous System Diseases; Creatinine; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Middle Aged; Neurofilament Proteins; Tenofovir | 2019 |
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Protease Inhibitors; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Pharmaceutical Preparations; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load | 2020 |
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
Topics: Adenine; Adult; Aged; Alanine; Benzimidazoles; Coinfection; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Sofosbuvir; Tenofovir | 2020 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug Substitution; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Nasopharyngitis; Renal Insufficiency; Respiratory Tract Infections; Sustained Virologic Response; Tenofovir | 2020 |
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Cross-Over Studies; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Organophosphates; Polyphosphates; Pre-Exposure Prophylaxis; Prospective Studies; Tenofovir; Young Adult | 2020 |
Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
Topics: Adult; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Tenofovir | 2021 |
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults
Topics: Adenine; Adult; Alanine; Amides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Mutation; Pilot Projects; Piperazines; Prospective Studies; Protease Inhibitors; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2020 |
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, n
Topics: Adenine; Adolescent; Adult; Alanine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Body Weight; Cyclopropanes; Duration of Therapy; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2020 |
Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials.
Topics: Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; HIV-1; Sequence Analysis, DNA; Tablets; Tenofovir; Viral Load | 2021 |
Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)
Topics: Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Tablets; Tenofovir | 2020 |
Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Glucose; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Insulin Resistance; Lamivudine; Lipids; Metabolic Syndrome; Oxazines; Piperazines; Pyridones; Tenofovir; Viral Load; Weight Gain | 2021 |
A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.
Topics: Adenine; Alanine; Anti-HIV Agents; Emtricitabine; Healthy Volunteers; HIV Infections; HIV-1; Humans; Male; Tenofovir | 2021 |
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; Gestational Age; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Oxazines; Piperazines; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pyridones; Tenofovir; Ultrasonography, Prenatal | 2021 |
Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.
Topics: Alanine; Amides; Anti-HIV Agents; Drug Combinations; Drug Resistance; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; Tenofovir | 2021 |
Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate.
Topics: Alanine; Antiviral Agents; Hepatitis B; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2022 |
Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
Topics: Adolescent; Adult; Alanine; Antiviral Agents; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2021 |
Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
Topics: Acute-On-Chronic Liver Failure; Adenine; Adult; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome | 2021 |
Bioequivalence Evaluation of Two Formulations of Tenofovir Alafenamide Tablets in Healthy Subjects Under Fasting and Fed Conditions.
Topics: Adolescent; Adult; Alanine; Antiviral Agents; Area Under Curve; Cross-Over Studies; Fasting; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Tablets; Tenofovir; Therapeutic Equivalency; Young Adult | 2021 |
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome; Young Adult | 2021 |
Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
Topics: Alanine; Antiviral Agents; Female; Fumarates; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infectious Disease Transmission, Vertical; Pregnancy; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Black or African American; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Piperazines; Pyridones; RNA; Tenofovir; United States; Viral Load | 2021 |
Tenofovir alafenamide fumarate therapy in subjects with positive HBV-DNA and normal levels of alanine transaminase: a study protocol for a randomised controlled trial.
Topics: Adult; Alanine; Alanine Transaminase; DNA, Viral; Double-Blind Method; Fumarates; Humans; Randomized Controlled Trials as Topic; Tenofovir | 2021 |
Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.
Topics: Alanine; Anti-HIV Agents; Diphosphates; Emtricitabine; HIV Infections; Humans; Leukocytes, Mononuclear; Tenofovir | 2021 |
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Child; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Middle Aged; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Young Adult | 2021 |
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
Topics: Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Piperazines; Pyridones; Retrospective Studies; Tenofovir | 2022 |
CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women.
Topics: Alanine; Anti-HIV Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Delayed-Action Preparations; Female; HIV Infections; Humans; Tenofovir | 2022 |
Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Dyslipidemias; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipids; Male; Middle Aged; Tenofovir | 2022 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 F
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Oxazines; Piperazines; Pyridones; RNA; Tenofovir | 2022 |
Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study.
Topics: Adenine; Alanine; Antiviral Agents; DNA, Viral; Female; Fumarates; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome | 2022 |
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Cobicistat; Darunavir; DNA; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Tandem Mass Spectrometry | 2023 |
247 other study(ies) available for alanine and gs-7340
| Article | Year |
|---|---|
Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Area Under Curve; CD4-Positive T-Lymphocytes; Chromatography, High Pressure Liquid; Dogs; HIV-1; Humans; In Vitro Techniques; Lymphatic System; Male; Organophosphonates; Prodrugs; Reverse Transcriptase Inhibitors; Spectrophotometry, Ultraviolet; Tenofovir; Tissue Distribution | 2005 |
Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus.
Topics: Adenine; Administration, Oral; Administration, Topical; Alanine; Animals; Anti-HIV Agents; Genetic Predisposition to Disease; Macaca mulatta; Organophosphonates; Prodrugs; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Virulence | 2006 |
Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131.
Topics: Adenine; Alanine; Anti-Retroviral Agents; Catalysis; Cathepsin A; Cell Size; Cells, Cultured; Enzyme Activation; Fibroblasts; Humans; Hydrolysis; Kinetics; Monocytes; Prodrugs; Recombinant Proteins; Substrate Specificity; Tenofovir | 2007 |
Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases.
Topics: Adenine; Alanine; Anti-HIV Agents; beta-N-Acetylhexosaminidases; Biomarkers; Cathepsin A; Cells, Cultured; Enzyme Activation; Humans; Hydrolysis; Kinetics; Leukocytes, Mononuclear; Lysosomes; Molecular Structure; Organophosphonates; Peptide Hydrolases; Prodrugs; Reverse Transcriptase Inhibitors; Serine Endopeptidases; Subcellular Fractions; Substrate Specificity; Tenofovir | 2008 |
Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340.
Topics: Adenine; Administration, Oral; Alanine; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cathepsin A; Chromatography, Liquid; Dogs; Humans; Intestinal Absorption; Lymphocytes; Male; Prodrugs; Tandem Mass Spectrometry; Tenofovir | 2013 |
Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cytokines; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Longitudinal Studies; Macaca mulatta; Male; Organophosphorus Compounds; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Statistics, Nonparametric; Tenofovir; Viremia | 2012 |
Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro.
Topics: Adenine; Alanine; Caco-2 Cells; Carbamates; Cobicistat; HIV Protease Inhibitors; Humans; Intestinal Absorption; Tenofovir; Thiazoles | 2012 |
Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+ T-cells and macrophages from demographically diverse donors.
Topics: Adenine; Alanine; Anti-HIV Agents; Antiviral Agents; Cathepsin A; CD4-Positive T-Lymphocytes; Cells, Cultured; Enzyme Activation; HIV-1; Humans; Leukocytes, Mononuclear; Macrophages; Tenofovir; Tissue Donors | 2014 |
Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity.
Topics: Adenine; Alanine; Antiviral Agents; Biological Transport; Cell Line; Cells, Cultured; Gene Expression; Humans; Kidney Tubules, Proximal; Organic Anion Transport Protein 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Tenofovir | 2014 |
Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy.
Topics: Adenine; Alanine; Animals; Cells, Cultured; Dogs; Hepatitis B virus; Hepatocytes; Humans; Liver; Male; Organophosphates; Tenofovir | 2015 |
Tenofovir alafenamide for HIV infection: is less more?
Topics: Adenine; Alanine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2015 |
Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; Drug Implants; Equipment Design; HIV Infections; HIV-1; Male; Monocytes; Prodrugs; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.
Topics: Adenine; Alanine; Amino Acid Substitution; Anti-HIV Agents; Biotransformation; Cell Line; Clone Cells; Drug Resistance, Viral; Drug Stability; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Leukocytes, Mononuclear; Lymphocytes; Microbial Sensitivity Tests; Mutation; Primary Cell Culture; Prodrugs; Tenofovir; Virus Replication | 2015 |
In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
Topics: Adenine; Alanine; Anti-HIV Agents; Biotransformation; Cell Line; Culture Media; Drug Stability; Genotype; Herpesvirus 2, Human; HIV-1; Humans; Inhibitory Concentration 50; Leukocytes, Mononuclear; Lymphocytes; Microbial Sensitivity Tests; Primary Cell Culture; Prodrugs; Serum; Tenofovir; Virus Replication | 2015 |
Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors.
Topics: Adenine; Alanine; Anti-HIV Agents; Biotransformation; Carboxylic Ester Hydrolases; Cathepsin A; CD4-Positive T-Lymphocytes; Cobicistat; Drug Interactions; Gene Expression; HEK293 Cells; HeLa Cells; HIV-1; Host-Pathogen Interactions; Humans; Oligopeptides; Primary Cell Culture; Prodrugs; Proline; RNA, Small Interfering; Serine Proteinase Inhibitors; Tenofovir | 2016 |
Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity?
Topics: Adenine; Alanine; Antiviral Agents; Clinical Trials, Phase III as Topic; Creatinine; Drug Approval; Drug Combinations; Glomerular Filtration Rate; Humans; Kidney Tubules, Proximal; Prodrugs; Tenofovir | 2016 |
Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.
Topics: Acute Kidney Injury; Adenine; Alanine; Anti-HIV Agents; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Male; Middle Aged; Salvage Therapy; Tenofovir | 2016 |
[New NRTI with optimized long-term tolerance].
Topics: Adenine; Alanine; Anti-HIV Agents; Drug Combinations; Drug Tolerance; HIV Infections; Humans; Tenofovir | 2015 |
A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis.
Topics: Adenine; Alanine; Anti-HIV Agents; Biodegradable Plastics; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Fumarates; HIV-1; Particle Size; Polyesters; Polymers; Pre-Exposure Prophylaxis; Solubility; Tenofovir | 2016 |
Editorial.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Tenofovir | 2016 |
First case report of renal improvement on tenofovir alafenamide in an HIV/hepatitis B virus-coinfected patient with adefovir-induced Fanconi's syndrome.
Topics: Absorptiometry, Photon; Adenine; Alanine; Coinfection; Dose-Response Relationship, Drug; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2016 |
[Brief notes. Approval recommendation for fixed combination Descovy(R) in treatment of HIV].
Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Child; Dose-Response Relationship, Drug; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; Humans; Tenofovir; Young Adult | 2016 |
Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment.
Topics: Adenine; Aged; Alanine; Anti-HIV Agents; Area Under Curve; Case-Control Studies; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Tenofovir | 2016 |
[Optimized therapy].
Topics: Adenine; Alanine; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Europe; HIV Infections; Humans; Tenofovir | 2016 |
Chemoprophylaxis With Oral Emtricitabine and Tenofovir Alafenamide Combination Protects Macaques From Rectal Simian/Human Immunodeficiency Virus Infection.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Chemoprevention; Emtricitabine; Macaca; Simian Acquired Immunodeficiency Syndrome; Tenofovir; Treatment Outcome | 2016 |
Antiretroviral treatment for HIV infection: Swedish recommendations 2016.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Early Detection of Cancer; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Piperazines; Pre-Exposure Prophylaxis; Pyridones; Sweden; Tenofovir | 2017 |
[Tenofovir alafenamide fumarate - a new generation of tenofovir].
Topics: Adenine; Alanine; Anti-HIV Agents; Drug Combinations; HIV Infections; Humans; Tenofovir | 2016 |
Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro.
Topics: Adenine; Alanine; Antiviral Agents; Drug Resistance, Viral; Genotype; Hep G2 Cells; Hepatitis B; Hepatitis B virus; Humans; Mutagenesis, Site-Directed; Phenotype; Prodrugs; Tenofovir; Virus Replication | 2017 |
Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.
Topics: Adenine; Alanine; Animals; Delayed-Action Preparations; Disease Transmission, Infectious; Female; HIV Infections; Injections, Subcutaneous; Mice; Mice, SCID; Nanoparticles; Plasma; Quinolones; Tenofovir; Treatment Outcome; Vagina; Viral Load | 2017 |
Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.
Topics: Adenine; Alanine; Cell Survival; Cells, Cultured; Cytotoxins; Dose-Response Relationship, Drug; Female; Humans; Male; Osteoblasts; Tenofovir; Time Factors | 2017 |
Evolution of tenofovir-resistant HIV-1 isolates exposed to tenofovir alafenamide dose escalation.
Topics: Adenine; Alanine; Anti-HIV Agents; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Viral; Evolution, Molecular; Genotype; HEK293 Cells; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Mutation; Phenotype; Prodrugs; Recombination, Genetic; Tenofovir | 2017 |
Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.
Topics: Adenine; Alanine; Anti-HIV Agents; Coinfection; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome | 2017 |
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; Europe; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation, Missense; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine; United States | 2017 |
[Update in HIV therapy: tenofovir alafenamide].
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Prodrugs; Tenofovir | 2016 |
Improvement in renal function and resolution of proteinuria in an HIV-infected patient switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Alanine; Antiviral Agents; Drug Substitution; Female; HIV Infections; Humans; Kidney Diseases; Middle Aged; Proteinuria; Tenofovir | 2017 |
Simultaneous determination of tenofovir alafenamide and its active metabolites tenofovir and tenofovir diphosphate in HBV-infected hepatocyte with a sensitive LC-MS/MS method.
Topics: Adenine; Alanine; Anti-HIV Agents; Cell Line, Tumor; Chromatography, Liquid; DNA Replication; Half-Life; Hep G2 Cells; Hepatocytes; HIV Infections; HIV-1; Humans; Organophosphates; Prodrugs; Tandem Mass Spectrometry; Tenofovir; Virus Replication | 2017 |
Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Mitochondria; Prodrugs; Tenofovir | 2017 |
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxazines; Piperazines; Proportional Hazards Models; Pyridones; Quinolones; Raltegravir Potassium; Ritonavir; Tenofovir; Treatment Outcome | 2018 |
Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
Topics: Adenine; Adult; Alanine; Antiviral Agents; Coinfection; Drug Resistance, Viral; Female; Hepatitis B, Chronic; HIV Infections; Humans; Kidney Failure, Chronic; Renal Dialysis; Tenofovir; Treatment Outcome | 2017 |
Role of tenofovir alafenamide in the jungle of antiretroviral prescription.
Topics: Adenine; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Tenofovir | 2018 |
Regimen Change: Gilead's TAF Drugs Toppling TDFs in HIV Treatment.
Topics: Adenine; Alanine; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2017 |
Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Contraceptive Agents; Contraceptives, Oral, Hormonal; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphates; Progestins; Tenofovir | 2017 |
Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Chromatography, Liquid; Cross-Over Studies; Drug Substitution; Female; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Plasma; Prospective Studies; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2018 |
Establishment of intracellular tenofovir-diphosphate as the key determinant for in vitro-in vivo translation of antiviral efficacy.
Topics: Adenine; Alanine; Anti-HIV Agents; Cytoplasm; Databases, Factual; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Meta-Analysis as Topic; Organophosphates; Prodrugs; Tenofovir; Viral Load; Virus Replication | 2018 |
Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.
Topics: Adenine; Alanine; Anti-HIV Agents; Chromatography, Liquid; Humans; Organophosphonates; Prodrugs; Tandem Mass Spectrometry; Tenofovir | 2018 |
Antiviral Activity of Tenofovir Alafenamide Against HIV-1 Subtypes and Emergence of K65R.
Topics: Adenine; Alanine; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation, Missense; Selection, Genetic; Tenofovir | 2018 |
Translation of clinical trial data to changes in clinical practice: rapid transition from tenofovir disoproxil fumarate to tenofovir alafenamide-based therapies in a Sydney HIV clinic.
Topics: Adenine; Alanine; Ambulatory Care Facilities; Anti-HIV Agents; Antiviral Agents; Australia; HIV Infections; HIV-1; Humans; Medical Audit; Tenofovir; Treatment Outcome | 2018 |
Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals.
Topics: Adenine; Adolescent; Adult; Alanine; Anti-Retroviral Agents; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Male; Middle Aged; Tenofovir; Young Adult | 2018 |
To use entecavir, tenofovir disoproxil fumarate or tenofovir alafenamide: it's all about choosing the right patient!
Topics: Adenine; Alanine; Anti-HIV Agents; Guanine; HIV Infections; Humans; Tenofovir | 2018 |
Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Kidney Diseases; Tablets; Tenofovir | 2018 |
Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema.
Topics: Adenine; Administration, Rectal; Alanine; Animals; Anti-HIV Agents; Anti-Infective Agents; Enema; HIV Infections; HIV-1; Homosexuality, Male; Male; Mice; Organophosphates; Organophosphonates; Pre-Exposure Prophylaxis; Prodrugs; Rectum; Sexual and Gender Minorities; Tenofovir | 2019 |
What did we learn from the bictegravir switch studies?
Topics: Adenine; Adult; Alanine; Amides; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Protease Inhibitors; Pyridones; Tenofovir | 2018 |
Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient.
Topics: Acidosis, Lactic; Adenine; Aged; Alanine; Antiviral Agents; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Hepatitis B; Hepatitis C; HIV Infections; Humans; Male; Multiple Myeloma; Tenofovir; Transplantation, Autologous | 2018 |
A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cross-Sectional Studies; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Health Knowledge, Attitudes, Practice; Health Surveys; HIV Infections; Humans; Male; Middle Aged; Patient Satisfaction; Pharmacists; Tenofovir | 2018 |
Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics.
Topics: Actinobacteria; Adenine; Alanine; Anti-Retroviral Agents; Bacteria; Endocytosis; Female; Gardnerella vaginalis; HIV Infections; Humans; Hydrogen-Ion Concentration; Jurkat Cells; Lactobacillus crispatus; Microbiota; Pyrimidines; Tenofovir; Vagina | 2018 |
Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes.
Topics: Adenine; Alanine; Anti-Retroviral Agents; Deoxyadenosines; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Recombination, Genetic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2018 |
Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Overdose; Emtricitabine; HIV Infections; Humans; Male; Middle Aged; Quinolones; Renal Insufficiency; Suicide, Attempted; Tenofovir | 2019 |
A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2018 |
A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cohort Studies; Female; Fumarates; Germany; HIV Seropositivity; Hospitals, University; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Weight Gain; Weight Loss | 2019 |
Drug updates and approvals: 2018 in review.
Topics: Adenine; Alanine; Amides; Aminophenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzodioxoles; Clonidine; Doxylamine; Drug Approval; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; Humans; Indoles; Piperazines; Pyridones; Pyridoxine; Quinolones; Tenofovir; United States; United States Food and Drug Administration | 2018 |
Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cholesterol; Cholesterol, LDL; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Follow-Up Studies; HIV Infections; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Retrospective Studies; Risk Factors; Spain; Tenofovir; Young Adult | 2019 |
In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2.
Topics: Adenine; Alanine; Anti-HIV Agents; Drug Discovery; Drug Resistance, Multiple, Viral; HIV-2; Humans; Microbial Sensitivity Tests; Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2019 |
Abnormal elevation of international normalized ratio in a patient during the coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and warfarin: a case report.
Topics: Adenine; Alanine; Cobicistat; Emtricitabine; HIV Infections; Humans; International Normalized Ratio; Quinolones; Tenofovir; Warfarin | 2019 |
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Pelvic Bones; Phosphorous Acids; Prospective Studies; Spine; Tenofovir; Treatment Outcome; Young Adult | 2019 |
Fanconi Syndrome and Tenofovir Alafenamide: A Case Report.
Topics: Adenine; Alanine; Antiviral Agents; Fanconi Syndrome; HIV Infections; Humans; Male; Middle Aged; Tenofovir | 2019 |
Epithelial Cells and Fibroblasts from the Human Female Reproductive Tract Accumulate and Release TFV and TAF to Sustain Inhibition of HIV Infection of CD4+ T cells.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cervix Uteri; Drug Resistance, Multiple; Endometrium; Epithelial Cells; Female; Fibroblasts; Genitalia, Female; HIV Infections; Humans; Middle Aged; Organophosphates; Tenofovir; Vagina | 2019 |
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2019 |
Using artificial neural network and multivariate calibration methods for simultaneous spectrophotometric analysis of Emtricitabine and Tenofovir alafenamide fumarate in pharmaceutical formulation of HIV drug.
Topics: Adenine; Alanine; Anti-HIV Agents; Calibration; Emtricitabine; Least-Squares Analysis; Multivariate Analysis; Neural Networks, Computer; Spectrophotometry, Ultraviolet; Tenofovir | 2019 |
Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Antiviral Agents; Dogs; Madin Darby Canine Kidney Cells; Membrane Transport Proteins; Reverse Transcriptase Inhibitors; Tenofovir | 2019 |
[Marked improvement in renal tubular markers after switching from adefovir to tenofovir alafenamide in a case of Fanconi syndrome diagnosed through high ALP levels].
Topics: Adenine; Alanine; Alkaline Phosphatase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fanconi Syndrome; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Middle Aged; Organophosphonates; Tenofovir; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen.
Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Cell Count; Emtricitabine; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Metabolic Clearance Rate; Plasma; Semen; Tenofovir; Tissue Distribution | 2019 |
Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels: uncovering the mechanism of tenofovir disoproxil fumarate-related bone loss?
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Bone Resorption; Drug Substitution; Female; Humans; Male; Middle Aged; Parathyroid Hormone; Retrospective Studies; Tenofovir | 2019 |
Simultaneous determination of tenofovir alafenamide and tenofovir in human plasma by LC-MS/MS and its application to pharmacokinetics study in clinic.
Topics: Adenine; Adolescent; Adult; Alanine; Chromatography, Liquid; Female; Humans; Limit of Detection; Linear Models; Male; Middle Aged; Reproducibility of Results; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2019 |
Bictegravir and dolutegravir: head to head at 96 weeks.
Topics: Adenine; Alanine; Amides; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2019 |
A case of entecavir-induced Fanconi syndrome.
Topics: Acidosis; Acute Kidney Injury; Adenine; Aged; Alanine; Antiviral Agents; Fanconi Syndrome; Guanine; Hepatitis B, Chronic; Humans; Hypokalemia; Hypophosphatemia; Male; Nucleosides; Tenofovir; Treatment Outcome; Withholding Treatment | 2019 |
Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis.
Topics: Adenine; Alanine; Hepatitis B, Chronic; HIV Infections; Humans; Liver Transplantation; Tenofovir | 2020 |
Sustained HIV virologic suppression with crushed combination tablets containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Therapy, Combination; Emtricitabine; Enteral Nutrition; Gastrostomy; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Sustained Virologic Response; Tablets; Tenofovir | 2019 |
Tenofovir alafenamide fumarate attenuates bleomycin-induced pulmonary fibrosis by upregulating the NS5ATP9 and TGF-β1/Smad3 signaling pathway.
Topics: Adenine; Alanine; Animals; Antiviral Agents; Bleomycin; Cells, Cultured; DNA-Binding Proteins; Fibroblasts; Humans; Male; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Signal Transduction; Smad3 Protein; Tenofovir; Transforming Growth Factor beta1; Up-Regulation | 2019 |
Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Biomarkers; Cobicistat; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Quinolones; Sexual and Gender Minorities; Tenofovir; Time Factors; Young Adult | 2019 |
Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Chemoprevention; Disease Models, Animal; Disease Transmission, Infectious; Emtricitabine; Female; HIV; HIV Infections; Macaca; Pre-Exposure Prophylaxis; Simian Immunodeficiency Virus; Tenofovir; Treatment Outcome; Vagina | 2019 |
The determination of human peripheral blood mononuclear cell counts using a genomic DNA standard and application in tenofovir diphosphate quantitation.
Topics: Adenine; Alanine; Cell Count; Chromatography, High Pressure Liquid; DNA; Fluorescent Dyes; Genomics; Humans; Image Cytometry; Intercalating Agents; Leukocytes, Mononuclear; Organophosphates; Prodrugs; Tandem Mass Spectrometry; Tenofovir | 2019 |
Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Quinolones; Tenofovir | 2020 |
Switching antiretrovirals in older patients.
Topics: Adenine; Aged; Alanine; Bone Density; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Quinolones; Tablets; Tenofovir | 2019 |
Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Interactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Risk Factors; Switzerland; Tenofovir | 2019 |
Fanconi Syndrome and Tenofovir Alafenamide.
Topics: Adenine; Alanine; Anti-HIV Agents; Fanconi Syndrome; Humans; Tenofovir | 2019 |
Fanconi Syndrome and Tenofovir Alafenamide.
Topics: Adenine; Alanine; Anti-HIV Agents; Fanconi Syndrome; Humans; Tenofovir | 2019 |
Fevers and Night Sweats in a 35-year-old Man With Recent Travel to Southeast Asia.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Asia, Southeastern; Cobicistat; Emtricitabine; HIV Infections; Humans; Laos; Male; Quinolones; Sweating; Tenofovir; Thailand; Travel; United States | 2019 |
HIV 101: fundamentals of antiretroviral therapy.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Integrase Inhibitors; Lamivudine; Life Cycle Stages; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load | 2019 |
Where Were the Women? Gender Parity in Clinical Trials.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; Drug Combinations; Emtricitabine; Equivalence Trials as Topic; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Sex Factors; Tenofovir; United States; United States Food and Drug Administration | 2019 |
Decreased levels of urinary liver-type fatty acid-binding protein after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; beta 2-Microglobulin; Biomarkers; CD4 Lymphocyte Count; Creatinine; Fatty Acid-Binding Proteins; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2019 |
TAF and TDF attenuate liver fibrosis through NS5ATP9, TGFβ1/Smad3, and NF-κB/NLRP3 inflammasome signaling pathways.
Topics: Adenine; Alanine; Animals; Antiviral Agents; Carbon Tetrachloride; Disease Models, Animal; DNA-Binding Proteins; Liver Cirrhosis, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Smad3 Protein; Tenofovir; Transforming Growth Factor beta | 2020 |
Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cholesterol; Drug Substitution; Female; Germany; HIV Infections; HIV-1; Humans; Logistic Models; Male; Middle Aged; Retrospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
Topics: Adenine; Aged; Alanine; Antibodies, Viral; Antiviral Agents; Female; Fumarates; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Japan; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Surveys and Questionnaires; Tenofovir; Transaminases; Treatment Outcome | 2020 |
Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Substitution; Female; Glomerular Filtration Rate; HIV Infections; Hospitals, Urban; Humans; Kidney Function Tests; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Tenofovir | 2019 |
Response to Noe, Oldenbuettel and Jaeger.
Topics: Adenine; Alanine; HIV Infections; Humans; Tenofovir | 2020 |
A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Delayed-Action Preparations; Drug Implants; Female; Fumarates; HIV Infections; Humans; Inflammation; Macaca mulatta; Male; Necrosis; Polyurethanes; Rabbits; Subcutaneous Tissue; Tenofovir | 2020 |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Diamond; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load; Young Adult | 2020 |
Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Dyslipidemias; Emtricitabine; Female; HIV Seropositivity; Humans; Lipids; Male; Middle Aged; Quinolones; Retrospective Studies; Tenofovir; Weight Gain | 2020 |
Not all is perfect with Tenofovir alafenamide.
Topics: Adenine; Alanine; HIV Infections; Humans; Tenofovir | 2020 |
Tenofovir Alafenamide for HIV Preexposure Prophylaxis: What Can We DISCOVER About Its True Value?
Topics: Adenine; Alanine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2020 |
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
Topics: Adenine; Adult; Alanine; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Nucleotides; Platelet Count; Research Design; Risk; Tenofovir; Time Factors | 2020 |
Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Mutation; Piperazines; Pyridones; Tenofovir; Toxoplasmosis, Cerebral; Treatment Failure | 2020 |
An LC-MS/MS method for determination of tenofovir (TFV) in human plasma following tenofovir alafenamide (TAF) administration: Development, validation, cross-validation, and use of formic acid as plasma TFV stabilizer.
Topics: Adenine; Alanine; Anti-HIV Agents; Chromatography, Liquid; Formates; Humans; Prodrugs; Tandem Mass Spectrometry; Tenofovir | 2020 |
Development of gynecomastia following initiation of bictegravir/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Combinations; Emtricitabine; Gynecomastia; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2020 |
Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?
Topics: Age Factors; Alanine; Albuminuria; Cholesterol, LDL; Drug Substitution; Female; HIV Infections; Humans; Male; Middle Aged; Proteinuria; Retrospective Studies; Tenofovir; Time Factors | 2020 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide: perhaps not as simple as we thought.
Topics: Adenine; Alanine; Antiviral Agents; Cholesterol, LDL; Drug Monitoring; Drug Substitution; Glomerular Filtration Rate; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipid Metabolism; Risk Assessment; Tenofovir | 2020 |
How Much Are We Willing to Pay for Preexposure Prophylaxis in the United States?
Topics: Adenine; Alanine; Anti-HIV Agents; Cost-Benefit Analysis; Decision Making, Shared; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Health Services Accessibility; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; United States | 2020 |
Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Substitution; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Switzerland; Tenofovir | 2020 |
The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; Fumarates; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Rilpivirine; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Weight Gain | 2020 |
Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels.
Topics: Alanine; Antiviral Agents; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2021 |
Hypophosphatemic Osteomalacia Due to Adefovir-Induced Fanconi Syndrome.
Topics: Adenine; Aged; Alanine; Antiviral Agents; Fanconi Syndrome; Female; Hepatitis C, Chronic; Humans; Hypophosphatemia; Organophosphonates; Osteomalacia; Tenofovir | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cholesterol; Cholesterol, LDL; Cohort Studies; Female; HIV Infections; Humans; Lipid Metabolism; Lipids; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome | 2020 |
Pharmacokinetics of a weekly transdermal delivery system of tenofovir alafenamide in hairless rats.
Topics: Adenine; Administration, Cutaneous; Administration, Oral; Alanine; Animals; Antiviral Agents; Delayed-Action Preparations; Drug Administration Schedule; Drug Compounding; Female; Injections, Intravenous; Proof of Concept Study; Rats, Hairless; Tenofovir; Tissue Distribution; Transdermal Patch; Vagina | 2020 |
The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.
Topics: Adenine; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Monitoring; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; Humans; Lymphoid Tissue; Male; Tenofovir; Tissue Distribution; Treatment Outcome; Viral Load | 2020 |
Management Consideration in Drug-Induced Lactic Acidosis.
Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Alanine; Continuous Renal Replacement Therapy; Diabetes Mellitus, Type 2; Female; Heart Failure; HIV Infections; Humans; Oliguria; Reverse Transcriptase Inhibitors; Sodium Bicarbonate; Tenofovir | 2020 |
Satisfaction and knowledge among patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine
Topics: Adenine; Adult; Alanine; Antiviral Agents; Drug Combinations; Drug Substitution; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Rilpivirine; Tenofovir | 2020 |
Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.
Topics: Adenine; Aged; Alanine; Amides; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HEK293 Cells; HeLa Cells; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Male; Mutation; Piperazines; Pyridones; Tenofovir; Treatment Failure | 2020 |
Weighing considerations with newer antiretrovirals.
Topics: Adenine; Alanine; Amides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Tenofovir | 2020 |
Tenofovir Alafenamide Fumarate Therapy for HIV Treatment: Cardiometabolic and Renal Safety.
Topics: Alanine; Anti-HIV Agents; Cardiovascular Diseases; Female; Fumarates; HIV Infections; Humans; Kidney; Male; Retrospective Studies; Tenofovir | 2020 |
Interspecies Differences in Tenofovir Alafenamide Fumarate Stability in Plasma.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; Fumarates; HIV Infections; Rabbits; Sheep; Tenofovir | 2020 |
Tenofovir Alafenamide for HIV Preexposure Prophylaxis.
Topics: Adenine; Alanine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Tenofovir Alafenamide for HIV Preexposure Prophylaxis.
Topics: Adenine; Alanine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report.
Topics: Acute Disease; Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lipase; Male; Pancreas; Pancreatitis; Piperazines; Pyridones; Tenofovir; Ultrasonography | 2020 |
DISCOVER: much accomplished, but not yet for all.
Topics: Adenine; Alanine; Double-Blind Method; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Mutation; Quinolones; Retrospective Studies; Tenofovir | 2020 |
Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir.
Topics: Adenine; Alanine; Anti-HIV Agents; Benzimidazoles; Fluorenes; HIV Infections; Humans; Protease Inhibitors; Sofosbuvir; Tenofovir | 2020 |
Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case report.
Topics: Acute Disease; Alanine; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Chemotherapy-Induced Febrile Neutropenia; Deprescriptions; Drug Interactions; Fanconi Syndrome; Gentamicins; Glycosuria; HIV Infections; Hodgkin Disease; Humans; Hypokalemia; Hypophosphatemia; Male; Middle Aged; Proteinuria; Tenofovir | 2020 |
Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study.
Topics: Abnormalities, Drug-Induced; Adenine; Adult; Alanine; Chemoprevention; China; Cohort Studies; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infectious Disease Transmission, Vertical; Male; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Successful Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment in a HIV Patient With Swallowing Difficulties.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Deglutition; Drug Combinations; Emtricitabine; Female; Fruit and Vegetable Juices; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Middle Aged; Piperazines; Pyridones; Solubility; Tenofovir | 2021 |
Characterization of Hepatitis B virus polymerase mutations A194T and CYEI and tenofovir disoproxil fumarate or tenofovir alafenamide resistance.
Topics: Alanine; Drug Resistance, Viral; Hepatitis B virus; Humans; Mutation; Tenofovir | 2021 |
Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
Topics: Adenine; Aged; Alanine; Anti-HIV Agents; Female; Glomerular Filtration Rate; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Interrupted Time Series Analysis; Kidney Diseases; Kidney Function Tests; Liver; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load | 2020 |
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis.
Topics: Adenine; Alanine; Cost-Benefit Analysis; Emtricitabine; Family; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis.
Topics: Adenine; Alanine; Cost-Benefit Analysis; Emtricitabine; Family; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS
Topics: Adult; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Female; Genitalia; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Piperazines; Prospective Studies; Pyridones; Rectum; RNA; Tenofovir | 2021 |
Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Rifabutin; Tenofovir; Viral Load | 2020 |
Tenofovir alafenamide does not inhibit mitochondrial function and cholesterol biosynthesis in human T lymphoblastoid cell line.
Topics: Adenine; Alanine; Anti-HIV Agents; Cell Line; Cholesterol; DNA, Mitochondrial; HIV Infections; HIV-1; Humans; Membrane Potentials; Mitochondria; T-Lymphocytes; Tenofovir | 2020 |
HIV Antivirals Affect Endothelial Activation and Endothelial-Platelet Crosstalk.
Topics: 5'-Nucleotidase; Adenine; Alanine; Anti-HIV Agents; Apyrase; Blood Platelets; Cell Adhesion Molecules; Cell Communication; Cell-Derived Microparticles; Cells, Cultured; Dideoxynucleosides; Endothelial Cells; GPI-Linked Proteins; Human Umbilical Vein Endothelial Cells; Humans; Platelet Activation; Signal Transduction; Tenofovir; Thromboplastin | 2020 |
HCC risk reduction with oral nucleos(t)ide analogues in patients with chronic hepatitis B: Not perfect, not good enough.
Topics: Adenine; Administration, Oral; Alanine; Carcinoma, Hepatocellular; DNA, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Nucleotides; Tenofovir | 2020 |
Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance?
Topics: Alanine; Dyslipidemias; HIV Infections; Humans; Tenofovir | 2021 |
Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
Topics: Adult; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2021 |
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide discontinuation and return to normal weight.
Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Quinolones; Tenofovir; Weight Gain | 2021 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate: integrating systematic review findings into practice and policy.
Topics: Adenine; Alanine; HIV Infections; Humans; Policy; Tenofovir | 2020 |
Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.
Topics: Adenine; Alanine; Amides; Animals; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Homosexuality, Male; Humans; Leukocytes, Mononuclear; Macaca; Male; Piperazines; Pre-Exposure Prophylaxis; Pyridones; Sexual and Gender Minorities; Tenofovir | 2021 |
Editorial: tenofovir alafenamide fumarate-a new bullet to prevent mother-to-child transmission of hepatitis B virus. Authors' reply.
Topics: Adenine; Alanine; Child; Cohort Studies; Female; Fumarates; Hepatitis B virus; Humans; Infectious Disease Transmission, Vertical; Safety; Tenofovir | 2020 |
Editorial: tenofovir alafenamide fumarate-a new silver bullet to prevent mother-to-child transmission of hepatitis B virus.
Topics: Adenine; Alanine; Child; Cohort Studies; Female; Fumarates; Hepatitis B virus; Humans; Infectious Disease Transmission, Vertical; Safety; Tenofovir | 2020 |
PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
Topics: Adenine; Alanine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir; United States | 2021 |
Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience.
Topics: Adenine; Alanine; HIV Infections; Humans; Liver Transplantation; Retrospective Studies; Tenofovir | 2021 |
Prescribing rates and characteristics of recipients of tenofovir-containing regimens before and after market entry of tenofovir alafenamide.
Topics: Alanine; Anti-HIV Agents; Antiviral Agents; Comorbidity; Drug Approval; HIV Infections; Humans; Practice Patterns, Physicians'; Tenofovir; United States; United States Food and Drug Administration | 2020 |
Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Emtricitabine; Female; HIV Infections; Humans; Postpartum Period; Pregnancy; Prospective Studies; Tenofovir | 2021 |
Tenofovir alafenamide revisited.
Topics: Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Drug Substitution; HIV Infections; Humans; Tenofovir | 2020 |
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients.
Topics: Adult; Alanine; Anti-HIV Agents; Cobicistat; Cohort Studies; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolones; Taiwan; Tenofovir | 2021 |
Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Postoperative Complications; Quinolones; Tenofovir; Viral Load | 2020 |
Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients With Chronic Hepatitis B.
Topics: Alanine; Alanine Transaminase; Antiviral Agents; Diabetes Mellitus; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.
Topics: Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Quinolones; Tenofovir; Young Adult | 2021 |
Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study.
Topics: Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Tenofovir; Viral Load | 2021 |
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospective Studies; Tenofovir; Treatment Outcome; Viremia | 2021 |
The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study.
Topics: Acute-On-Chronic Liver Failure; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospective Studies; Tenofovir; Treatment Outcome | 2021 |
Assessment of the greenness of new stability indicating micellar UPLC and HPTLC methods for determination of tenofovir alafenamide in dosage forms.
Topics: Adenine; Alanine; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Micelles; Reproducibility of Results; Tablets; Tenofovir | 2021 |
Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems.
Topics: Adult; Aged; Alanine; Antiviral Agents; Asian; Black or African American; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Mortality; Propensity Score; Proportional Hazards Models; Retrospective Studies; Safety-net Providers; Tenofovir; United States; Urban Population; White People | 2021 |
Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
Topics: Adult; Aged; Alanine; Alanine Transaminase; DNA, Viral; Drug Substitution; Female; Glomerular Filtration Rate; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Liver; Liver Function Tests; Male; Middle Aged; Prodrugs; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Tenofovir | 2021 |
Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan.
Topics: Adult; Alanine; Anti-HIV Agents; Fumarates; HIV Infections; HIV-1; Humans; Japan; Prospective Studies; Tenofovir | 2021 |
Summary for Patients: Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV.
Topics: Adult; Alanine; Anti-HIV Agents; HIV Infections; Humans; Lipids; Obesity; Tenofovir; Weight Gain | 2021 |
Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
Topics: Adult; Alanine; Anti-HIV Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; HIV Infections; Humans; Lipids; Male; Middle Aged; Obesity; Sensitivity and Specificity; Tenofovir; Triglycerides; Weight Gain | 2021 |
Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study.
Topics: Alanine; Canada; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir | 2021 |
A rare case of acute tubular necrosis tenofovir alafenamide-related.
Topics: Adenine; Alanine; HIV Infections; Humans; Necrosis; Tenofovir | 2021 |
Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog.
Topics: Adult; Aged; Alanine; Antiviral Agents; Aspirin; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Guanine; Hepatitis B, Chronic; Hong Kong; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir | 2021 |
Inhibition of Bitter Taste from Oral Tenofovir Alafenamide.
Topics: Adenine; Adult; Alanine; Antiviral Agents; Cell Line; Female; Flavones; Flavoring Agents; HEK293 Cells; Humans; Male; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Taste; Taste Buds; Tenofovir | 2021 |
Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Diabetes Mellitus, Type 2; Female; HIV Infections; Humans; Male; Middle Aged; Sustained Virologic Response; Tenofovir; Treatment Outcome; Weight Gain | 2021 |
Increase in Body Mass Index in Children With HIV, Switched to Tenofovir Alafenamide Fumarate or Dolutegravir Containing Antiretroviral Regimens.
Topics: Adolescent; Alanine; Anti-Retroviral Agents; Body Mass Index; Child; Cohort Studies; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Weight Gain | 2021 |
Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.
Topics: Alanine; Alanine Transaminase; Anti-HIV Agents; Cohort Studies; Fumarates; Hepatitis, Viral, Human; HIV Infections; Humans; Male; Middle Aged; Switzerland; Tenofovir | 2021 |
Brief Report: No Difference in Urine Tenofovir Levels in Patients Living With HIV on Unboosted Versus Dose-Adjusted Boosted Tenofovir Alafenamide.
Topics: Adenine; Alanine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chromatography, Liquid; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Point-of-Care Systems; San Francisco; Tandem Mass Spectrometry; Tenofovir | 2021 |
Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis.
Topics: Adolescent; Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Viral Load | 2021 |
[Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients].
Topics: Adolescent; Adult; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; Tenofovir | 2021 |
Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study.
Topics: Alanine; Anti-HIV Agents; Biomarkers; Fumarates; HIV Infections; Humans; Kidney; Lipids; Prospective Studies; Tenofovir | 2021 |
Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV.
Topics: Adenine; Adult; Alanine; Amides; Antiretroviral Therapy, Highly Active; BNT162 Vaccine; CD4 Lymphocyte Count; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; COVID-19; COVID-19 Vaccines; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Neutralization Tests; Piperazines; Pyridones; RNA, Viral; SARS-CoV-2; Tenofovir; Treatment Failure | 2021 |
Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection.
Topics: Alanine; Amides; Anti-HIV Agents; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Piperazines; Pyridones; Tenofovir | 2021 |
Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.
Topics: Adenine; Aged; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2021 |
Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Immunosuppressive Agents; Kidney Transplantation; Piperazines; Protease Inhibitors; Pyridones; Tacrolimus; Tenofovir | 2022 |
A 28-Day Toxicity Study of Tenofovir Alafenamide Hemifumarate by Subcutaneous Infusion in Rats and Dogs.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; Edema; HIV Infections; HIV-1; Infusions, Subcutaneous; Male; Organophosphates; Pre-Exposure Prophylaxis; Rats; Tenofovir | 2021 |
Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
Topics: Adenine; Alanine; Anti-HIV Agents; Cohort Studies; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.
Topics: Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
Topics: Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Tenofovir | 2021 |
Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.
Topics: Alanine; Anti-HIV Agents; Drug Substitution; HIV Infections; Humans; Integrase Inhibitors; Retrospective Studies; Tenofovir; Weight Gain | 2022 |
Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen.
Topics: Alanine; Anti-HIV Agents; Body Mass Index; Case-Control Studies; Comorbidity; Female; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Weight Gain | 2021 |
Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV.
Topics: Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Piperazines; Pyridones; Tenofovir | 2021 |
Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.
Topics: Alanine; Anti-HIV Agents; Cardiovascular Diseases; Heart Disease Risk Factors; HIV Infections; Humans; Lipids; Retrospective Studies; Risk Factors; Tenofovir; Weight Gain | 2021 |
Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Creatinine; Cystatin C; Female; HIV Infections; Humans; Kidney Diseases; Kidney Tubules, Proximal; Male; Middle Aged; Tenofovir | 2021 |
Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Drug Stability; Female; HIV Infections; HIV-1; Humans; Male; Nanoparticles; Organophosphates; Prodrugs; Rats, Sprague-Dawley; Tenofovir; Therapeutic Equivalency | 2021 |
Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization.
Topics: Alanine; Anti-HIV Agents; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Retrospective Studies; Tenofovir | 2021 |
Combination Treatment with the Vimentin-Targeting Antibody hzVSF and Tenofovir Suppresses Woodchuck Hepatitis Virus Infection in Woodchucks.
Topics: Alanine; Animals; Antibodies, Monoclonal, Humanized; Antiviral Agents; Disease Models, Animal; Drug Therapy, Combination; Endocytosis; Hep G2 Cells; Hepatitis B; Hepatitis B Virus, Woodchuck; Host-Pathogen Interactions; Humans; Liver; Marmota; Tenofovir; Vimentin; Viral Load; Virus Internalization; Virus Replication | 2021 |
Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide
Topics: Adenine; Alanine; Body Weight; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir | 2022 |
Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV.
Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cobicistat; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Quality of Life; Quinolones; Sleep Quality; Tenofovir | 2021 |
Analytical Lifecycle Management (ALM) and Analytical Quality by Design (AQbD) for analytical procedure development of related substances in tenofovir alafenamide fumarate tablets.
Topics: Adenine; Alanine; Anti-HIV Agents; Chromatography, Liquid; Fumarates; HIV Infections; Humans; Tablets; Tenofovir | 2022 |
Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Topics: Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer.
Topics: Adenine; Aged; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Male; Oxazines; Pancreatic Neoplasms; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2022 |
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.
Topics: Aged; Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Tenofovir; Treatment Outcome | 2021 |
Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Piperazines; Pyridones; Rifampin; Tenofovir | 2021 |
Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network.
Topics: Adenine; Alanine; Anti-HIV Agents; Female; HIV; HIV Infections; Humans; Pregnancy; Pregnant Women; Tenofovir | 2022 |
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir.
Topics: Alanine; Amides; Anti-HIV Agents; Dideoxynucleosides; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2022 |
Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study.
Topics: Alanine; Anti-HIV Agents; Fumarates; HIV Infections; HIV-1; Humans; Japan; Kidney; Tenofovir | 2021 |
Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on estimated glomerular filtration rate slope in patients with HIV: A retrospective observational study.
Topics: Alanine; Anti-HIV Agents; Fumarates; Glomerular Filtration Rate; HIV Infections; Humans; Retrospective Studies; Tenofovir | 2022 |
Contributions of Cathepsin A and Carboxylesterase 1 to the Hydrolysis of Tenofovir Alafenamide in the Human Liver, and the Effect of CES1 Genetic Variation on Tenofovir Alafenamide Hydrolysis.
Topics: Alanine; Carboxylesterase; Carboxylic Ester Hydrolases; Cathepsin A; Genetic Variation; Humans; Hydrolysis; Liver; Tenofovir | 2022 |
Effects of Genetic Polymorphisms of Cathepsin A on Metabolism of Tenofovir Alafenamide.
Topics: Alanine; Cathepsin A; Healthy Volunteers; Humans; Japan; K562 Cells; Polymorphism, Genetic; Tenofovir | 2021 |
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.
Topics: Adenine; Alanine; Cholesterol; Hepatitis B, Chronic; Humans; Propensity Score; Tenofovir | 2022 |
Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Fatigue; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Piperazines; Post-Exposure Prophylaxis; Pyridones; Tenofovir | 2022 |
Point-of-care semi-quantitative test for adherence to tenofovir alafenamide or tenofovir disoproxil fumarate.
Topics: Adult; Alanine; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Point-of-Care Systems; Tenofovir | 2022 |
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.
Topics: Adult; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Piperazines; Pyridones; Retrospective Studies; Tenofovir | 2022 |
Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Fumarates; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Renal Insufficiency, Chronic; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Tenofovir alafenamide: An initial experience at Groote Schuur Hospital, Cape Town, South Africa.
Topics: Adult; Alanine; Antiviral Agents; Female; Follow-Up Studies; Glomerular Filtration Rate; Hepatitis B; Hepatitis B e Antigens; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; South Africa; Tenofovir; Treatment Outcome; Viral Load | 2022 |
Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
Topics: Aged; Alanine; Antiviral Agents; Drug Substitution; Female; Follow-Up Studies; Fumarates; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Nucleosides; Prospective Studies; Tenofovir; Treatment Outcome | 2022 |
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles.
Topics: Adenine; Alanine; Dyslipidemias; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Case of psoriasis with hepatitis B virus infection during tumor necrosis factor inhibitor treatment successfully treated with ixekizumab and tenofovir alafenamide fumarate.
Topics: Adenine; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Fumarates; Hepatitis B; Hepatitis B virus; Humans; Psoriasis; Tenofovir; Tumor Necrosis Factor Inhibitors | 2022 |
Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Female; HIV Infections; Humans; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Protease Inhibitors; Tenofovir | 2022 |
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B.
Topics: Adenine; Alanine; Carcinoma, Hepatocellular; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Tenofovir | 2022 |
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Clinical Trials as Topic; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; RNA; Tenofovir | 2022 |
Bictegravir-based antiretroviral therapy in HIV-1 group O patients: data from real-life bictegravir/emtricitabine/tenofovir alafenamide switches.
Topics: Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Tenofovir | 2022 |
Tenofovir alafenamide fumarate.
Topics: Adenine; Alanine; Anti-HIV Agents; Fumarates; HIV Infections; HIV-1; Humans; Tenofovir | 2022 |
Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Female; HIV Infections; Mice; Tenofovir | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Female; Hepatitis B; Hepatitis B, Chronic; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Milk, Human; Pregnancy; Tenofovir | 2022 |
[Real-world efficacy of switching to bictegravir/ emtricitabine/tenofovir alafenamide in pretreated patients with triple therapy containing rilpivirine].
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; Rilpivirine; Tenofovir | 2022 |
Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cardiovascular Diseases; Cholesterol; Drug Substitution; Fumarates; HIV Infections; Humans; Retrospective Studies; Sustained Virologic Response; Tenofovir; Weight Gain | 2022 |
Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain.
Topics: Alanine; Anti-HIV Agents; Cholesterol, LDL; Drug Substitution; HIV Infections; Humans; Retrospective Studies; Tenofovir; Weight Gain | 2022 |
Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Topics: Adenine; Adult; Alanine; Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans; Renal Insufficiency, Chronic; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks.
Topics: Adenine; Adult; Alanine; Hepatitis B, Chronic; HIV Infections; Humans; Phosphates; Prospective Studies; Tenofovir | 2022 |
One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study.
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2022 |
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.
Topics: Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Viral Load; Viremia | 2022 |
HBV in pregnancy: time to consider tenofovir alafenamide (TAF).
Topics: Adenine; Alanine; Female; Hepatitis B virus; HIV Infections; Humans; Pregnancy; Tenofovir | 2022 |
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Piperazines; Pyridones; Tenofovir | 2022 |
Tenofovir Alafenamide use in pregnant women with chronic hepatitis B virus infection: more data needed.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Pregnancy; Pregnant Women; Tenofovir | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide of mothers with chronic hepatitis B infection-Authors' reply.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Milk, Human; Mothers; Tenofovir | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B, Chronic; HIV Infections; Humans; Milk, Human; Mothers; Tenofovir | 2022 |
Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.
Topics: Adenine; Alanine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Retrospective Studies; Tenofovir | 2022 |
Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients-author's reply.
Topics: Adenine; Alanine; Bone Density; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir | 2022 |
Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B.
Topics: Adenine; Alanine; Bone Density; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir | 2022 |
Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Kidney; Longitudinal Studies; Maleates; Organophosphonates; Renal Insufficiency, Chronic; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B.
Topics: Adenine; Alanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B - author's reply.
Topics: Adenine; Alanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Effect of alcohol exposure on the efficacy and safety of tenofovir alafenamide fumarate, a major medicine against human immunodeficiency virus.
Topics: Adenine; Alanine; Alcohol Drinking; Anti-HIV Agents; Carboxylic Ester Hydrolases; Chromatography, Liquid; Ethanol; Fumarates; HIV; HIV Infections; Humans; Lipids; Organophosphates; Tandem Mass Spectrometry; Tenofovir | 2022 |
Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
Topics: Adenine; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cholesterol, LDL; Cobicistat; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lamivudine; Lipoproteins, HDL; Quinolones; Retrospective Studies; Tenofovir | 2022 |
Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy.
Topics: Acute Kidney Injury; Adenine; Alanine; Antiviral Agents; Cisplatin; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Kidney; Neoplasms; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study-IMEA 055.
Topics: Adenine; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Prospective Studies; Pyridones | 2023 |
No evidence of rapid reversibility of tenofovir alafenamide and/or integrase strand transfer inhibitor-associated weight gain.
Topics: Adult; Alanine; Anti-Retroviral Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Virus Integration; Weight Gain | 2023 |
Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir.
Topics: Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lipoproteins, HDL; Male; Middle Aged; Pyridones | 2023 |